

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: randomised, active-controlled, observer-blinded, phase 3 trial

Joon Young Song^a, MD, Won Suk Choi^b, MD, Jung Yeon Heo^c, MD, Eun Jin Kim^c, MD, Jin Soo Lee^d, MD, Dong Sik Jung^e, MD, Shin-Woo Kim^f, MD, Kyung-Hwa Park^g, MD, Joong Sik Eom^h, MD, Su Jin Jeongⁱ, MD, Jacob Lee^j, MD, Ki Tae Kwon^k, MD, Hee Jung Choi^l, MD, Jang Wook Sohn^m, MD, Young Keun Kimⁿ, MD, Byung Wook Yoo^o, MD, In-Jin Jang^p, MD, Maria R. Capeding^q, MD, François Roman^r, MD, Thomas Breuer^s, MD, Piotr Wysocki^t, MPharm, Lauren Carter^u, M.Sc, Sushant Sahastrabudhe^v, MBBS, Manki Song^v, PhD, Naveena D'Cor^w, MD, Hun Kim^w PhD, Ji Hwa Ryu^w, MS, Su Jeon Lee^w, PhD, Yong Wook Park^w, MS, Hee Jin Cheong^a, MD

^aDivision of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea (JY Song, HJ Cheong);

^bDivision of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea (WS Choi);

^cDepartment of Infectious Diseases, Ajou University School of Medicine, Suwon, Republic of Korea (JY Heo, EJ Kim);

^dDivision of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea (JS Lee);

^eDivision of Infectious Diseases, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea (DS Jung);

^fDivision of Infectious Diseases, Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea (SW Kim);

^gDivision of Infectious Diseases, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea (KH Park);

^hDivision of Infectious Diseases, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea (JS Eom);

ⁱDivision of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea (SJ Jeong);

^jDivision of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Republic of Korea (J Lee);

^kDivision of Infectious Diseases, Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea (KT Kwon);

^lDivision of Infectious Diseases, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea (HJ Choi);

^mDivision of Infectious Diseases, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea (JW Sohn);

Division of Infectious Diseases, Department of Internal Medicine, Yonsei University Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea (YK Kim);

ⁿDepartment of Family Medicine, Soon Chun Hyang University Hospital, Seoul, Republic of Korea (BW Yoo);

^pDepartment of Clinical Pharmacology and Therapeutics, College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea (IJ Jang);

^qTropical Disease Foundation – San Francisco Multi-purpose Bldg, Laguna 4000, Philippines (M. R. Capeding);

^rGlaxoSmithKline Vaccines, Wavre, Belgium (F Roman, T Breuer);

^sGlaxoSmithKline Vaccines, Warsaw, Poland (P Wysocki);

^tDepartment of Biochemistry, University of Washington, WA, U.S. (L Carter);

^uInstitute for Protein Design, University of Washington, WA, U.S. (L Carter);

^vInternational Vaccine Institute, Seoul, Republic of Korea (S Sahastrabudhe, M Song, N D'Cor);

^wDepartment of R&D, SK Bioscience, Seongnam, Republic of Korea (H Kim, JH Ryu, SJ Lee, YW Park)

Corresponding author: Hee Jin Cheong, MD, PhD, Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Gurodong-ro 148, Guro-gu, Seoul 08308, Republic of Korea; Tel.: +82-2-2626-3050, Fax: +82-2-2626-1105, E-mail: heejinmd@korea.ac.kr

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Background: GBP510 vaccine contains self-assembling, recombinant nanoparticles displaying SARS-CoV-2 spike receptor-binding domains. We report interim phase 3 immunogenicity results for GBP510 adjuvanted with AS03 (GBP510/AS03) compared with ChAdOx1-S (Vaxzevria, AstraZeneca) up to 2 weeks after the second dose, and safety data up to a median of 2.5 months follow-up.

Methods: Randomised, active-controlled, observer-blinded, multinational study: Cohort 1 (no history of SARS-CoV-2 infection/COVID-19 vaccination, n=1956) randomised 2:1 to receive two doses of GBP510/AS03 or ChAdOx1-S (immunogenicity and safety); Cohort 2 (regardless of baseline serostatus; n=2080) randomised 5:1 (safety). Primary objectives: demonstrate superiority in geometric mean titre (GMT) and non-inferiority in seroconversion rate (SCR; ≥ 4 -fold rise from baseline) of GBP510/AS03 versus ChAdOx1-S for neutralising antibodies against the ancestral strain by live-virus neutralisation assay. Secondary objectives included assessment of safety and reactogenicity.

Findings: At 2 weeks after the second vaccination, the GMT ratio (GBP510/AS03 / ChAdOx1-S) was 2.93 (95% CI 2.63–3.27), demonstrating superiority (95% CI lower limit > 1). The between-group SCR difference of 10.76% (95% CI 7.68–14.32) satisfied the non-inferiority criterion (95% CI lower limit $> -5\%$). The proportion of subjects with adverse events (AEs) after any vaccination was higher with GBP510/AS03 versus ChAdOx1-S for solicited local AEs (56.69% vs 49.20%), but was similar for solicited systemic AEs (51.21% vs 53.51%) and unsolicited AEs (13.27% vs 14.56%). No safety concerns were identified during follow-up for a median 2.5-months after the second vaccination.

Interpretation: GBP510/AS03 met the superiority criterion for neutralising antibodies and non-inferiority criterion for SCR compared with ChAdOx1-S, and showed a clinically acceptable safety profile.

Funding: This work was supported, in whole or in part, by funding from CEPI and the Bill & Melinda Gates Foundation Investments INV-010680 and INV-006462. The Bill & Melinda Gates Foundation supported this project for the generation of IND-enabling data and CEPI supported this clinical study.

RESEARCH IN CONTEXT

Evidence before this study: Immunobridging has been proposed as an approach for assessing new COVID-19 vaccines by comparing the immunogenicity of candidate vaccines with an active comparator with demonstrated clinical efficacy. We searched PubMed up to 26 October 2022 for immunobridging clinical trials comparing a candidate vaccine with an approved vaccine, using the terms “immunobridging”, “SARS-CoV-2”, “COVID-19”, and “vaccine”. A phase 2/3 study showed that the ChAdOx1 vaccine, manufactured by the Serum Institute of India after technology transfer from Oxford University/AstraZeneca, had a non-inferior immune response compared to the original ChAdOx1 (AZD1222) vaccine. A post hoc analysis of phase 2 data found that MVC-COV1901 vaccine (a protein subunit vaccine developed by Medigen Vaccine Biologics Corporation, Taiwan) was non-inferior to ChAdOx1 (AZD1222) with respect to neutralising antibody titres. A phase 3 study found that VLA2001 (an adjuvanted, inactivated whole-virus vaccine developed by Valneva, Austria) was superior to ChAdOx1 with respect to neutralising antibody titres and non-inferior with respect to seroconversion rates.

Added value of this study: This is the first study comparing the immunogenicity of recombinant SARS-CoV-2 protein nanoparticle vaccine GBP510 adjuvanted with AS03 versus ChAdOx1-S. Interim analysis found that two-dose vaccination with GBP510/AS03 induced stronger neutralising antibody immune responses compared with ChAdOx1-S against the ancestral D614G strain at 2 weeks after the second dose. GBP510/AS03 had an acceptable safety profile during a median 2.5 months of follow-up.

Implications of the available evidence: This interim analysis suggests that GBP510/AS03 induces strong neutralising antibody responses against SARS-CoV-2 ancestral strain and has an acceptable safety profile.

INTRODUCTION

Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on different underlying technologies, have been approved in different countries.¹

GBP510 is a recombinant protein vaccine consisting of self-assembling, two-component nanoparticles displaying SARS-CoV-2 spike receptor-binding domains (RBDs). It is adjuvanted with AS03, which contains α -tocopherol and squalene² and enhances the immune response to the vaccine antigen.³ The vaccine can be stored at regular refrigerator temperatures (2–8 °C) which makes it suitable for rollout in parts of the world where the requirement for ultra-cold chain handling can be challenging. A phase 1/2 study showed that GBP510 adjuvanted with AS03 (hereafter GBP510/AS03) was highly immunogenic and well tolerated in healthy adults aged 19–85 years.³

Thresholds for immune correlates of protection based on antibody levels or functional activity have not yet been established.⁴ However, in 2021, the International Coalition of Medicines Regulatory Authorities determined that immunobridging studies were acceptable as part of the strategy for assessing new COVID-19 vaccines,⁵ a position which has since been adopted by regulatory bodies, including members of the Access Consortium (national regulatory authorities of Australia, Canada, Singapore, Switzerland and the UK).⁶

The aim of the current study was to assess the immunogenicity and safety of GBP510/AS03 for the prevention of COVID-19, based on the assumption that neutralising antibody titres would predict efficacy against the parental D614G strain. The primary objective was to demonstrate that the immune response induced by two doses of GBP510/AS03 administered at a 1-month interval in seronegative adults was superior (based on geometric mean titre [GMT] of neutralising antibodies) and non-inferior (based on seroconversion rate [SCR]) to the immune response induced by two doses of the ChAdOx1-S vaccine (Vaxzevria, AstraZeneca)⁷ against the ancestral strain using live virus neutralising assays. The secondary objective was to assess the safety profile of GBP510/AS03 regardless of baseline serostatus.

Follow-up of participants until 12 months after their second vaccination is ongoing. The interim analysis reported here encompasses immunogenicity data up to 2 weeks and safety data up to a median of 2.5 months follow-up after the second dose (data cut-off 31 March 2022).

METHODS

Study design and participants

This was a randomised, active-controlled, observer-blinded, parallel group, phase 3 study, conducted at 38 sites across six countries (South Korea, Philippines, Thailand, Vietnam, Ukraine and New Zealand).

Healthy or medically stable adults aged ≥ 18 years were enrolled into one of two cohorts (Figure S1). Cohort 1 (Immunogenicity cohort) included subjects with no history of SARS-CoV-2 infection or COVID-19 vaccination (confirmed by a rapid antibody screening test). Cohort 2 (Safety cohort) enrolled subjects irrespective of their serostatus at screening. Subjects were excluded from either cohort if they met any of the following criteria: clinically significant respiratory symptoms, febrile illness, or acute illness within 72h; previous SARS or middle east respiratory syndrome (MERS) infection, or SARS/MERS vaccination; receipt of medications/vaccinations aimed at preventing COVID-19; immunocompromised conditions; autoimmune diseases; bleeding disorders, thrombocytopenia, thrombosis or capillary leak syndrome; malignancy within 1 year; hypersensitivity to any vaccines; receipt of any other vaccine between 4 weeks(2 weeks for influenza vaccines) before first and 28 days after last study vaccination; receipt of immunoglobulins, blood products or systemic corticosteroids within 12 weeks; meeting any restriction for ChAdOx1-S; significant unstable chronic illness; pregnancy or breast feeding.

The study was designed by SK Bioscience with support from GlaxoSmithKline (GSK), the International Vaccine Institute and the Coalition for Epidemic Preparedness Innovations (CEPI). The study was performed in accordance with the Declaration of Helsinki and the International Council for Harmonization Good Clinical Practice guidelines. The protocol (supplementary material) was approved by the Institutional Review Board for each participating health facility, and written informed consent was obtained from all participants. The reporting of this study complies with the Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement. This study is registered on ClinicalTrials.gov (NCT05007951).

Randomisation and masking

For Cohort 1 sites, participants were randomised in a 2:1 ratio to receive GBP510/AS03 or ChAdOx1-S. For Cohort 2 sites, participants were randomised in a 5:1 ratio to GBP510/AS03 or ChAdOx1-S. Centralised interactive response technology was used to randomly allocate participants to treatment according to pre-generated block randomisation schedules stratified by age (18–64 or ≥ 65 years) and trial site. Except for pharmacy staff and vaccinators, all other study and laboratory personnel, and participants were blinded to treatment assignment.

Procedures

The study vaccine GBP510, which contains self-assembling, two-component nanoparticles (RBD-16GS-I53-50) that display SARS-CoV-2 spike (S) protein RBDs, was developed by the Institute for Protein Design at the University of Washington and SK Bioscience. The AS03 adjuvant (an α -tocopherol-containing oil-in-water emulsion) was developed by GlaxoSmithKline.² The control vaccine ChAdOx1-S was Chimpanzee Adenovirus encoding the SARS-CoV-2 spike glycoprotein (Vaxzevria, AstraZeneca).⁸

Each participant received two intramuscular injections (0.5 mL volume) of vaccine into the deltoid muscle at a 28-day interval. Each dose of the GBP510/AS03 vaccine contained RBD 25 μ g (0.25 mL) adjuvanted with AS03 (0.25 mL). Each dose of ChAdOx1-S contained no less than 2.5×10^8 infectious units/0.5mL.

Safety evaluations were performed for all participants who received at least one dose of study intervention. Immunogenicity assessments were performed in Cohort 1 only.

All participants were observed for at least 30 minutes after each vaccination for immediate adverse events. Participants used diary cards to record solicited local adverse events (AEs) (redness, swelling, and pain at injection site) and solicited systemic AEs (fever, nausea/vomiting, diarrhoea, fatigue, myalgia, arthralgia, chills) for 7 days after each vaccination, and unsolicited AEs within 28 days after each vaccination. Serious AEs (SAEs), medically-attended AEs (MAAEs), AEs leading to study withdrawal, and AEs of special interest (AESIs; [Tables S1](#) and [S2](#)) were recorded throughout the entire study period. AE severity was based on the US Food and Drug Administration (FDA) toxicity grading scale.⁹ All solicited local and systemic AEs were considered related to the study intervention; the

causal relationship for unsolicited AE was assessed by the investigators. Safety data were reviewed during the study by an independent safety monitoring board.

Blood samples for assessment of IgG antibody response and neutralisation assays were planned to be obtained from Cohort 1 participants at baseline, 4 weeks after the first vaccination, and at 2 weeks, 4 weeks, 6 months, and 12 months after the second vaccination. Blood samples for cell-mediated immunity assessments were collected at baseline and 2 weeks, 6 months, and 12 months after the second vaccination from a subset of approximately 10% of Cohort 1, selected pragmatically in advance to retain the randomisation ratio between study groups.

The neutralising antibody response to SARS-CoV-2 was measured using a focus reduction neutralisation test (FRNT) which assesses neutralising antibody titres in serum induced by viral infection/vaccination with live virus. The IgG antibody response to SARS-CoV-2 RBD was measured using enzyme-linked immunosorbent assay (ELISA). Cell-mediated immune responses were assessed using FluoroSpot assays to measure cytokine secretion in cells induced by external antigens such as viruses or vaccines, and intracellular cytokine staining (ICS), a flow-cytometry-based assay that detects specific T-cell types (e.g. CD4+, CD8+) after cellular immunity is induced by external antigens. Cytokines included interferon (IFN)- γ , interleukin (IL)-2, tumour necrosis factor (TNF)- α , and IL-4.

Outcomes

The co-primary endpoints were neutralising antibody titres (GMT and SCR) to SARS-CoV-2 parental strain (D614G) measured by live virus neutralisation assay (FRNT) at 2 weeks after the second vaccination. Comparison between groups was measured as GMT ratio and SCR difference, defined as the percentage of participants with ≥ 4 -fold rise in live virus neutralising antibody titre from baseline to 2 weeks after the second vaccination.

Secondary immunogenicity endpoints included titres of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA and neutralising antibody to SARS-CoV-2 measured by live virus neutralisation assay, at each timepoint post-vaccination, measured as GMT, GMT ratio, geometric mean fold rise (GMFR) from baseline, SCR and SCR difference. Additionally, cell-mediated responses for cytokines, measured by FluoroSpot and, for CD4+ and CD8+ T-cells, measured by ICS, after the second vaccination were considered. Safety endpoints (secondary endpoints) included: immediate unsolicited systemic reactions (within 30 minutes post-

vaccination); solicited local and systemic AEs within 7 days post-vaccination; unsolicited AEs within 28 days post-vaccination; SAEs, MAAEs and AESIs during the whole study period.

The current interim analysis includes immunogenicity at 2 weeks and safety data (including immediate unsolicited systemic AEs, solicited local/systemic AEs, unsolicited AEs, SAEs, MAAEs, AEs leading to withdrawal, and AESIs) up to 4 weeks after the second vaccination (data cut-off 18 March 2022). Additionally, a median 2.5 months of safety follow-up after the last vaccination is included and contributed to the main safety data set (data cut-off 31 March 2022). Results for 6 and 12 months (durability of response and safety) are not yet available.

Statistical analysis

The sample size for Cohort 1 was based on neutralisation assay results from the Phase 3 study of ChAdOx1-S⁸ and the Phase 1/2 study for GBP510/AS03³ to demonstrate superiority of GMT ratio and non-inferiority of SCR difference in terms of neutralising antibody titres. The planned sample size for Cohort 1 was 1950 (1300 test group, 650 control group) and that for Cohort 2 was 2040 (1700 test group, 340 control group); overall, this would ensure safety data were available for at least 3000 recipients of the two-dose GBP510/AS03 regimen. This sample size was based on FDA guidance for vaccine industry,¹⁰ and may allow the observance of at least one adverse event occurring at a frequency of 1 in 1,000. If the true AE rate was 0.1%, there would be a 95.03% probability of observing at least 1 AE in a test group comprising 3000 subjects.

All participants who received at least one dose of study vaccine were included in the safety set. The full analysis set comprised all participants who received at least 1 dose of the study vaccine and had valid pre- and at least one post-vaccination immunogenicity assessment results. The interim analysis of immunogenicity was primarily reported for the per-protocol population (baseline neutralising antibody titer was below LLOQ in wild-type virus neutralisation assay and completed vaccination schedule without SARS-CoV-2 infection with no major protocol deviations).

For the co-primary endpoints, adjusted post-vaccination GMT ratio estimate and 95% CIs were determined using analysis of covariance (ANCOVA) on log-transformed titres with treatment group and age (18–64 or ≥ 65 years) as factors, and baseline antibody level (titre) as covariate, while the 95% CIs for the difference in SCRs were calculated based on Chan and Zhang methodology. Superiority of post-vaccination GMT was demonstrated if the lower limit of the

two-sided 95% CI for the ratio of post-vaccination GMTs at 2 weeks after the second study vaccination (GBP510/AS03 / ChAdOx1-S) was greater than 1. Non-inferiority of SCR was demonstrated if the lower limit of the two-sided 95% CI for the difference in the percentage of participants with a ≥ 4 -fold rise from baseline in neutralisation antibody titre at 2 weeks after the second vaccination (GBP510/AS03 – ChAdOx1-S) exceeded the non-inferiority margin of –5%. For secondary immunogenicity endpoints, point estimates and 95% CI, or summary statistics (n, mean, SD, median, min and max), were presented for each treatment group. For safety endpoints, number and percentages of participants with at least one AE were presented by treatment group.

Role of the funding source

The funders had no role in the study design, collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. All authors had full access to all the data in the study and responsibility for the decision to submit for publication.

RESULTS

Characteristics of participants

Between 30 August 2021 and 10 February 2022, a total of 4036 participants (1956 in Cohort 1 and 2080 in Cohort 2) were randomised to receive GBP510/AS03 (n=3039) or ChAdOx1-S (n=997); [Figure 1](#). After exclusion of 11 randomised individuals who did not receive vaccine, the safety dataset included 4025 subjects (3029 in the GBP510/AS03 group and 996 in the ChAdOx1-S group). Among Cohort 1 participants, 1887 (1259 in the GBP510/AS03 group and 628 in the ChAdOx1-S group) received at least 1 dose of the study vaccine and had valid pre- and at least one post-vaccination immunogenicity results (full analysis set). The per-protocol set for the interim analysis of immunogenicity included 1318 subjects (877 in the GBP510/AS03 group and 441 in the ChAdOx1-S group) ([Figure S2](#)).

The demographics and baseline characteristics of study participants are summarised in [Table 1](#). Most subjects were Southeast Asian (81.47%). There were more males (59.12%) than females (40.88%). The mean age of subjects was 38.20±13.83 years; the mean age of the GBP510/AS03 group was slightly lower than that of the ChAdOx1-S group (37.83±13.84

versus 39.31 ± 13.77 , $p=0.0034$). However, the age strata distribution did not differ between the groups, with a total of 94.67% of subjects aged 18–64 years. The mean body mass index was 23.67 ± 4.33 kg/m².

Immunogenicity outcomes

Live virus neutralisation assays (FRNT)

The co-primary endpoints were based on measurement of the neutralising antibody response (ND₅₀ presented as IU/mL using the WHO standard) to SARS-CoV-2 using live virus neutralisation assays (FRNT). Post-vaccination GMTs were adjusted for age group (18–64 or ≥65 years) and baseline antibody level.

At baseline, there was no significant difference in GMT between the GBP510/AS03 group and the ChAdOx1-S group. At 4 weeks after the first vaccination, GMT (Figure 2), GMFR, and SCR were higher in the ChAdOx1-S group than in the GBP510/AS03 group, with between-group differences for the GMT ratio and SCR achieving statistical significance (Table 2).

At 2 weeks after the second vaccination (when the co-primary endpoints were evaluated), GMT (Figure 2) and SCR were higher in the GBP510/AS03 group than in the ChAdOx1-S group, as follows. The adjusted GMT ratio (GBP510/AS03 / ChAdOx1-S) was 2.93 (95% CI 2.63–3.27), which was statistically significantly different from 1 ($p<0.0001$) and satisfying the hypothesis of superiority (lower limit of 95% CI greater than 1);. The between-group difference in the SCR was 10.76% (95% CI 7.68–14.32), satisfying the hypothesis of non-inferiority (lower limit of 95% CI greater than –5%);. The test for independence between SCR and group was statistically significant ($p<0.0001$). In addition, the GMFR (\pm SD) was also higher in the GBP510/AS03 group (36.76 ± 2.54) than in the ChAdOx1 group (12.58 ± 2.76) at 2 weeks after the second vaccination (Table 2).

In subgroup analyses, similar results were seen at 2 weeks after the second vaccination in younger (18–64 years) and older (≥65 years) age groups (Tables S3–S4), in male and female, and across ethnicities (Korean, Southeast Asian and Caucasian; Tables S5), and results in participants who were seropositive for neutralising antibody at baseline (\geq LLOQ) were consistent with the seronegative population.

In addition, neutralising antibody GMTs at 2 weeks after the second vaccination (FRNT presented as ND₅₀) were higher with GBP510/AS03 than with ChAdOx1-S against the Delta

(B.1.617.2) variant (2644.2 vs 96.96; GMT ratio 27.27 [95% CI 18.88–39.39], $p < 0.0001$), the Omicron BA.1 (B.1.1.529) variant (129.09 vs 12.27; GMT ratio 10.52 [95% CI 8.18–13.53], $p < 0.0001$), and the Omicron BA.5 sub-lineage (61.61 vs 13.56; GMT ratio 4.54 [95% CI 3.51–5.88], $p < 0.0001$) in a subset of participants (Tables S6–S8).

Enzyme-linked immunosorbent assay (ELISA)

The GMTs of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA at baseline were similar between the two groups with no significant difference. At both 4 weeks after the first vaccination, and at 2 weeks after the second vaccination, GMT, GMFR, and the SCR were higher in the GBP510 group than in the ChAdOx1-S group, with differences in the GMT ratio and SCR achieving statistical significance at both timepoints (both $p < 0.0001$) (Table 3, Figure S3).

Cell-mediated immune response

The cell-mediated immune response was evaluated in a subset of Cohort 1 participants. At 2 weeks after the second vaccination, the median cell count for IFN γ , TNF- α , and IL-2 increased from baseline in both groups based on FluoroSpot assays (Table 4, Figures S4–S6). In particular, noticeable increases in TNF- α response (from median 23.00 at baseline to 52.00 spot forming cell (SFC) / 2.5×10^5 peripheral blood mononuclear cells (PBMCs)) and IL-2 response (from 24.00 at baseline to 57.00 SFC/ 2.5×10^5 PBMCs) were seen in the GBP510/AS03 group. No change in IL-4 was seen in either group (Table 4, Figure S7).

In ICS assessments of CD4⁺ T cells, some response was observed for TNF α and IL-2 in the GBP510/AS03 group (Table 4, Figures S8–S11). No response was observed in CD8⁺ T cells in either group (Table S9).

Safety outcomes

Of 3029 subjects in the GBP510/AS03 group and 996 subjects in the ChAdOx1-S group analysed for the Safety Set, immediate systemic AEs (occurring within 30 minutes) after any vaccination were reported by six subjects (0.20%) in the GBP510/AS03 group and in no subjects in the ChAdOx1-S group.

Solicited local AEs after any vaccination had a higher incidence in the GBP510/AS03 group (56.69% of subjects) than in the ChAdOx1-S group (49.20% of subjects; $p < 0.0001$). Injection site pain was the most common solicited local AE in both groups, reported by 55.69% of subjects in the GBP510/AS03 group and 48.80% of subjects in the ChAdOx1-S group; injection site redness was reported by 5.25% and 2.01% of subjects, and injection site swelling by 5.55% and 1.20% of subjects (Figure 3).

Solicited systemic AEs after any vaccination were reported by 51.21% of subjects in the GBP510/AS03 group and 53.51% of subjects in the ChAdOx1-S group ($p = 0.2058$). Headache (29.88% vs 33.23%), fatigue (31.07% vs 32.83%), and myalgia (30.47% vs 30.82%) were the most commonly reported solicited systemic AEs in both groups after any vaccination. In the GBP510/AS03 group, the frequency of solicited systemic AEs was similar after the first and second doses, while in the ChAdOx1-S group the frequency was higher after the first dose than after the second dose (Figure 3).

Most solicited local and systemic AEs were grade 1 (mild) or 2 (moderate) in severity and lasted a mean of 1.3 to 3.1 days for both groups (Figure 3, Tables S10 and S11). The proportion of participants who reported grade 3 (severe) solicited local AE after any vaccination was 1.85% in the GBP510/AS03 group and 0.60% in the ChAdOx1-S group. Grade 3 solicited systemic AEs were reported by 5.28% of participants in GBP510/AS03 group and 6.12% in ChAdOx1-S group. No grade 4 (potentially life threatening) solicited AEs were reported in either group.

The proportions of subjects aged 18–64 years with solicited local/systemic AEs were 56.70%/51.41% in the GBP510/AS03 group and 49.42%/53.67% in the ChAdOx1-S group, and in subjects aged ≥ 65 years were 56.33%/47.47% and 45.45%/50.91%, respectively. The proportion of Korean subjects reporting solicited local/systemic AEs (96.94%/93.58% in the GBP510/AS03 group and 85.12%/92.86% in the ChAdOx1-S group) was higher than seen among Southeast Asian subjects (49.90%/43.95% and 39.68%/43.76%, respectively).

Unsolicited AEs occurring within 28 days after any vaccination were reported by 13.27% of subjects in the GBP510/AS03 group and 14.56% of subjects in the ChAdOx1-S group ($p = 0.3040$), including 3.50% and 4.12%, respectively, of unsolicited adverse drug reactions (ADRs) ($p = 0.3679$) (Table S12). The most commonly reported unsolicited AEs by System Organ Class (SOC) were ‘Infections and infestations’ in both the GBP510/AS03 (5.91% of subjects) and the ChAdOx1-S (5.92% of subjects) groups, which were predominantly due to COVID-19 infections. Most unsolicited AEs after any vaccination were grade 1 (mild) or 2

(moderate) in severity. Unsolicited AEs of grade ≥ 3 severity occurred in 0.66% of subjects in the GBP510/AS03 group and 1.20% in the ChAdOx1-S group ($p=0.0932$).

MAAEs were reported for 7.49% of subjects in the GBP510/AS03 group and 8.43% of subjects in the ChAdOx1-S group, including 0.63% and 1.00% of subjects, respectively, with MAADRs (Table 5).

SAEs were reported for 0.83% of subjects in the GBP510/AS03 group and 0.80% in the ChAdOx1-S group. One event of rapidly progressive glomerulonephritis in the GBP510/AS03 group was assessed as a suspected unexpected serious adverse reaction (SUSAR) and AESI (Table 5). As a conservative judgement, the investigator reported it as a vaccine-related event due to the temporal relationship with GBP510/AS03 administration, and because a causal relationship with GBP510/AS03 could not be fully excluded. However, the clinical presentation and available laboratory findings do not provide evidence to establish a possible autoimmune aetiology for this event.

A total of 5 AESIs were reported; 2 in the GBP510/AS03 group (acute kidney injury and rapidly progressive glomerulonephritis) and 3 in the ChAdOx1-S group (acute pancreatitis, anaphylactic reaction, and psoriasis), of which only rapidly progressive glomerulonephritis was reported as a vaccine-related event.

One death occurred in the GBP510/AS03 group (brain neoplasm) and one death in ChAdOx1-S group (cardiorespiratory failure), with neither considered to be related to the study vaccines.

Five pregnancies were reported in the GBP510/AS03 group and two in the ChAdOx1-S group; the pregnancies were ongoing at the data lock point of the analysis, without any abnormal outcomes or SAEs reported during the reporting period. Three subjects in the GBP510/AS03 group and two in the ChAdOx1-S withdrew due to AEs, with one subject in the GBP510/AS03 group reported to have vaccine-related AEs (urticaria rash, injection site pain, headache, fatigue, myalgia, and arthralgia), all of which recovered/were resolved.

There were 336 virologically-confirmed (by PCR) or suspected (diagnosed with rapid antigen test) COVID-19 cases, 238 cases (7.86%) in the GBP510/AS03 group and 98 (9.84%) in the ChAdOx1-S group (Tables S13 and S14). All COVID-19 cases were either non-severe or asymptomatic, as per WHO criteria, thus, they were not suspected as vaccine-associated enhanced disease/vaccine-associated enhanced respiratory disease. However, COVID-19 was classified as an SAE in 0.33% of subjects in the GBP510/AS03 group and 0.40% in the ChAdOx1-S group, with the seriousness criterion being hospitalization. COVID-19 infected

patients in some countries (e.g., Thailand) were required, under local regulations, to be monitored or treated in hospital regardless of their severity of symptoms or medical history; these were subsequently considered as serious COVID-19 cases.

DISCUSSION

This interim analysis found that the immune response induced by two doses of GBP510/AS03 in seronegative adults was superior compared to ChAdOx1-S with respect to GMTs, and non-inferior with respect to SCRs, in terms of neutralising antibody response against the parental D614G strain of SARS-CoV-2 at 2 weeks after the second vaccination (primary endpoints). ELISA assessments of SARS-CoV-2 RBD-binding IgG antibody also indicated a higher immune response with GBP510/AS03 than with ChAdOx1-S at 2 weeks after the second vaccination.

Higher neutralising antibody responses were seen with GBP510/AS03 against the parental strain regardless of age or gender. In addition, a trend towards higher neutralising antibody responses against the Delta and Omicron variants was observed with GBP510/AS03 in comparison with ChAdOx1-S in a subset of participants.

Of note, when an additional analysis was performed in the subset to observe the trend in neutralising antibody response after interim analysis by FRNT, the GMT ratio of the two groups at 4 weeks after the second vaccination showed a similar trend to that seen at 2 weeks after the second vaccination (GMT ratio: 3.01 [95% CI 2.30–3.94]), whereas SCR in the ChAdOx1-S group showed a noticeable decrease compared to the GBP510/AS03 group (SCR: 94.74% [180/190 subjects; GBP510/AS03] and 68.18% [60/88 subjects; ChAdOx1-S]).

GBP510/AS03 had previously been found to be highly immunogenic in a phase 1/2 study.³ In that study, two-dose vaccination with GBP510 (25 µg RBD per dose)/AS03 induced high neutralising antibody titres measured by wild-type virus assay (plaque-reduction neutralisation test), with an increase in GMT from 4.33 at baseline to 861 IU/mL at 2 weeks after the second dose. Direct comparison with the current study is not possible because a different assay method (FRNT) was used; however, a high response was also seen in our study (GMT increased from 8.18 to 272.12 IU/mL). In the phase 1/2 study, a high geometric mean concentration of IgG antibody measured by ELISA was seen at 2 weeks after the second dose (2599 BAU/mL),³ which is consistent with the level observed at that timepoint in our study (2850.45 BAU/mL).

A noticeable increase in antibody responses after the second dose was observed compared to the first dose in both the phase 1/2³ and this phase 3 study, which may be due to some CD4+ T-cell response that was observed by ICS assessments after GBP510/AS03 vaccination. With CD4+ T-cell help, activated B cells initiate a germinal centre reaction, resulting in the generation of high-affinity memory B-cells and plasma cells, which are differentiated to antibody-secreting cells and provide overlapping layers of protection.^{11,12} A superior antigen-specific CD4+ T-cell response was also reported with AS03-adjuvantation in a randomised influenza vaccine trial.¹³

GBP510/AS03 showed a clinically acceptable safety profile, and no safety concerns were noted during the study up to a median 2.5 months after the second vaccination. The incidence rates of unsolicited AEs and SAEs were similar between the study groups. Reactogenicity after any vaccination was higher with GBP510/AS03 than with ChAdOx1-S in terms of local solicited AEs, especially after the second vaccination, but was similar to ChAdOx1-S in terms of systemic solicited AEs (being lower after the first vaccination with GBP510/AS03, but higher after the second one, compared with ChAdOx1-S). Both local and systemic solicited AEs were mostly mild or moderate in intensity in both groups.

In the current study, GBP510/AS03 showed lower reactogenicity than that observed in the phase 1/2 study,³ which could be explained by a difference in study populations. Higher rates of solicited AEs were observed in Korean participants compared with Southeast Asians (who constituted the majority of study participants). The rates seen in Korean participants were consistent with those seen in the phase 1/2 study, which included only Korean subjects.³

One of the main limitations of the data generated in this study is that the absence of vaccine efficacy data, and the lack of established correlates of protection for COVID-19 vaccines, make it difficult to extrapolate the results of the study. Although thresholds for immune correlates of protection based on antibody levels or functional activity have not yet been established, COVID-19 vaccine studies that have reported vaccine efficacy have shown robust correlations between antibody responses (neutralising antibody or binding antibody titres) and vaccine efficacy, despite the use of different assays, endpoints, and study populations.^{4,14-16} Another limitation is the small number of elderly participants due to high vaccination coverage in the elderly at the time of enrolment; however, the available results suggest that the immunogenicity of GBP510/AS03 against the parental strain was consistent across all age strata. The study included mostly Asian subjects, and did not include individuals with severe or unstable comorbid conditions, those who were immunocompromised, or pregnant or lactating women,

and post-authorisation studies are needed to collect safety data in these populations. The main immunogenicity results from the study are for the D614 strain, whereas the current epidemiological context is dominated by Omicron subvariants; however, analysis in a subset of participants provided some evidence of neutralising antibody responses against Omicron BA.1 and BA.5 after vaccination with GBP510/AS03. Furthermore, additional studies are ongoing to evaluate the immunogenicity and safety of homologous and heterologous booster vaccination with GBP510/AS03. Finally, safety data for this interim analysis were only available up to a median 2.5 months after the second vaccination; however, the study is ongoing and additional data up to 12 months of follow-up will become available in due course.

In conclusion, this interim analysis found that two-dose vaccination with GBP510/AS03 induced stronger neutralising antibody immune responses compared with ChAdOx1-S against the ancestral D614G strain at 2 weeks after the second vaccination, and had a clinically acceptable safety profile.

Contributors

HJC, HK, JHR, SJL, HKP, YWP, YYL, LC, FR, MC,TB, FS, PW, AP, and SGK contributed to the conception and design of this study. SS and PT contributed to the project administration. WSC, JYH, JSL, DSJ, SWK, KHP, JSE, SJJ, JL, KTK, HJC, JWS, YKK, HJC, BWY, IJJ, EJK, JC, EA, SN,WR, PM, RC, LQ, OK, TY, VK, AB, OG, OB, MP, CT, SC, SS, MW, THS, TH, DS, and MRC were the principal investigators of the study site. WSC, JYH, JSL, DSJ, SWK, KHP, JSE, SJJ, JL, KTK, HJC, JWS, YKK, BWY, IJJ, EJK, JYS, HJC, JC, EA, SN,WR, PM, RC, LQ, OK, TY, VK, AB, OG, OB, MP, CT, SC, SS, MW, THS, TH, DS, and MRC contributed to the acquisition of the clinical and laboratory data. BS and SS contributed to the resources of the study. SD contributed to the clinical operation. SS and MS contributed to the supervision of the study. JYS, SJJ, YKK, BWY, IJJ, PW, FR, MC,TB, and HJC contributed to the interpretation of the data. JYS and HJC had full access to and verify all of the data in the study and take responsibility for the integrity of the data. SS, ND, and SD contributed to the review and edit of the manuscript. JYS and HJC prepared the manuscript and had responsibility for the decision to submit the manuscript. All authors reviewed the manuscript for intellectual content and approved the final draft for submission. All authors have full access to all the data in the study and accept responsibility to submit for publication. All authors critically reviewed and approved the final version.

Declaration of interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: MA, FS, FR, AP, TB, and PW are employees of the GSK group of companies. MC, FR, TB, and AP hold restricted shares in the GSK group of companies. HK, JHR, SJL, YWP, HKP, YYL, and SGK are full-time employees of SK Bioscience. HK, YWP, JHR, YYL, and HKP own SK Bioscience stock as employees. HKP and YYL participated in the blinded session of data safety monitoring board as observers (NCT05007951). SS, MS, ND, PT, SD, SS, and BS are full-time employees of IVI. All other authors declare no competing interests.

Data sharing

Individual participant data will be made available when the trial is complete upon requests directed to the corresponding author. Proposals will be reviewed and approved by the sponsor, investigators, and collaborators on the basis of scientific merit. After approval of a proposal, data can be shared through a secure online platform.

Acknowledgements

This study was supported, in whole or in part, by the Bill & Melinda Gates Foundation (BMGF) and the Coalition for Epidemic Preparedness Innovations (CEPI). The authors thank David P. Figgitt PhD, ISMPP CMPP™, and Katherine F. Croom, Content Ed Net, for providing editorial support during the preparation of the manuscript, with funding from SK Bioscience.

Supplementary materials

Supplementary material associated with this article can be found in the online version at *medrxiv.org*

REFERENCES

- 1 Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. *Clin Microbiol Infect* 2022; **28**: 202–21.
- 2 Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. *Vaccine* 2011; **29**: 2461–73.
- 3 Song JY, Choi WS, Heo JY, et al. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. *EClinicalMedicine* 2022; **51**: 101569.
- 4 Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A covid-19 milestone attained — a correlate of protection for vaccines. *N Engl J Med* 2022; **387**: 2203–6.
- 5 International Coalition of Medicines Regulatory Authorities. ICMRA COVID-19 Vaccine Development: Future Steps Workshop. 24 June 2021. Available online: <http://www.icmra.info/drupal/en/covid-19/24june2021> (accessed August 26, 2022).
- 6 Medicines and Healthcare Products Regulatory Agency, UK. Access Consortium: Alignment with ICMRA Consensus on Immunobridging for Authorising New COVID-19 Vaccines. 15 September 2021. Available online: <https://www.gov.uk/government/publications/access-consortium-alignment-with-icmra-consensus-on-immunobridging-for-authorising-new-covid-19-vaccines/access-consortium-alignment-with-icmra-consensus-on-immunobridging-for-authorising-new-covid-19-vaccines> (accessed August 26, 2022).
- 7 Falsey AR, Sobieszczyk ME, Hirsch I, et al.; AstraZeneca AZD1222 Clinical Study Group. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *N Engl J Med* 2021; **385**: 2348–60.
- 8 European Medicines Agency. (2021). Vaxzevria (previously COVID-19 Vaccine AstraZeneca): EPAR - Product information. https://www.ema.europa.eu/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf (accessed August 26, 2023).
- 9 US Food and Drug Administration. Guidance for Industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. September 2007. <http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf> (accessed January 17, 2023).
- 10 US Food and Drug Administration. Guidance for Industry: Development and Licensure of Vaccines to Prevent COVID-19. June 30, 2020. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19> (accessed January 17, 2023).
- 11 Crotty S. A brief history of T cell help to B cells. *Nat Rev Immunol* 2015; **15**: 185–9.
- 12 Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS-CoV-2. *Nat Rev Immunol* 2022; **22**: 7–18.

- 13 Couch RB, Bayas JM, Caso C, et al. Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. *BMC Infect Dis* 2014; **14**: 425.
- 14 Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021; **27**: 1205–11.
- 15 Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* 2021; **39**: 4423–8.
- 16 Feng S, Phillips DJ, White T, et al.; Oxford COVID Vaccine Trial Group. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med* 2021; **27**: 2032–40.

Table 1 Demographics and baseline characteristics

	GBP510/AS03 (N=3039)	ChAdOx1-S (N=997)	Total (N=4036)
Age (years), mean \pm SD	37.83 \pm 13.84*	39.31 \pm 13.77*	38.20 \pm 13.83
18–64 years, n (%)	2878 (94.70)	943 (94.58)	3821 (94.67)
\geq 65 years, n (%)	161 (5.30)	54 (5.42)	215 (5.33)
Male/Female, n (%)			
Male	1814 (59.69)	572 (57.37)	2386 (59.12)
Female	1225 (40.31)	425 (42.63)	1650 (40.88)
Race, n (%)			
Asian	2856 (93.98)	931 (93.38)	3787 (93.83)
Korean	329 (10.83)	168 (16.85)	497 (12.31)
Southeast Asian	2526 (83.12)	762 (76.43)	3288 (81.47)
Other Asian	1 (0.03)	1 (0.10)	2 (0.05)
Caucasian	177 (5.82)	64 (6.42)	241 (5.97)
Black	0	0	0
Hispanic	0	0	0
Other	6 (0.20)	2 (0.20)	8 (0.20)
Body mass index (kg/m ²), mean \pm SD	23.59 \pm 4.35	23.90 \pm 4.27	23.67 \pm 4.33
Concomitant illness, n (%)	486 (15.99)	204 (20.46)	690 (17.10)
Concomitant medication, n (%)	1232 (40.54)	411 (41.22)	1643 (40.71)

* Between group p=0.0034.

Table 2 Immunogenicity assessment: neutralising antibody response to SARS-CoV-2 measured by live-virus neutralisation assays (FRNT). GMT, GMFR and SCR at 2 weeks after the second dose of vaccine were co-primary endpoints (per-protocol set)

	GBP510/AS03 (N=877)	ChAdOx1-S (N=441)
Neutralising antibodies GMT (IU/mL)		
GMT at baseline (95% CI)	8.18 (8.14–8.22)	8.13 (8.09–8.17)
GMT ratio (95% CI)	1.01 (1.00–1.01)	
P-value ^a	0.0936	
GMT ^b at 4 weeks after first dose (95% CI)	10.97 (8.43–14.28)	40.36 (30.45–53.51)
GMT ratio (95% CI)	0.27 (0.21–0.36)	
P-value ^c	<0.0001	
GMFR (95% CI)	1.39 (1.24–1.56)	5.10 (3.98–6.55)
GMT ^b at 2 weeks after second dose (95% CI)	272.12 (240.40–308.02)	92.75 (80.79–106.48)
GMT ratio (95% CI)*	2.93 (2.63–3.27)	
P-value ^c	<0.0001	
Superiority proven (lower limit of 95% CI for ratio of GMTs >1)	Yes	
GMFR (95% CI)	36.76 (34.56–39.11)	12.58 (11.44–13.83)
Seroconversion rate (SCR)		
SCR at 4 weeks after first dose [n/N] (95% CI)	5.64% [11/877] (2.85–9.87)	56.25% [54/441] (45.75–66.36)
Difference in SCR (95% CI)	–50.61% (–60.89 to –39.62)	
P-value ^d	<0.0001	
SCR at 2 weeks after second dose [n/N] (95% CI)	98.06% [860/877] (96.91–98.87)	87.30% [385/441] (83.83–90.26)
Difference in SCR (95% CI)*	10.76% (7.68–14.32)	
P-value ^d	<0.0001	
Non-inferiority proven (lower limit of 95% CI for SCR difference between groups > –5%)	Yes	

GMT ratio = GBP510/AS03 / ChAdOx1-S. Difference in SCR = GBP510/AS03 – ChAdOx1-S.

GMT = anti-logarithm [mean of natural logarithm (titre at visit n)]. SCR = percentage of participants with ≥4-fold rise from baseline. 95% confidence intervals for GMT calculated using Wald method with t-distribution. 95% CI for percentage of participants with ≥4-fold rise calculated using Clopper-Pearson method. 95% CI for difference between groups calculated using Chan and Zhang method.

^a Between-group difference (two sample t-test).

^b Adjusted post-vaccination GMT was used in the superiority test. Post-vaccination GMT was adjusted for age group (18–64 years, ≥65 years) and baseline antibody level.

^c Analysis of covariance (ANCOVA) with treatment group, age group (18–64, ≥65 years) as factors, and baseline antibody level as covariate.

^d Between-group difference (chi-square test).

* = Co-primary Endpoint (superiority based on the 2-sided 95% CI of the ratio of post-vaccination GMT (GBP510 over ChAdOx1-S); non-inferiority based on the 2-sided 95% CI of the difference in the percentages of participants with ≥ 4 -fold rise from baseline (GBP510 – ChAdOx1-S) in neutralization antibody titer).
CI = confidence interval; FRNT = focus reduction neutralization test; GMFR = geometric mean fold rise; GMT = geometric mean titre; SCR = seroconversion rate.

Table 3 Immunogenicity assessment: SARS-CoV-2 RBD-binding IgG antibody measured using ELISA (secondary endpoints; per-protocol set)

	GBP510/AS03 (N=877)	ChAdOx1-S (N=441)
ELISA GMT (BAU/mL)		
GMT at baseline (95% CI)	10.91 (10.51–11.32)	10.79 (10.27–11.34)
GMT ratio (95% CI)	1.01 (0.95–1.08)	
P-value ^a	0.7409	
GMT ^b at 4 weeks after first dose (95% CI)	131.24 (117.90–146.09)	91.91 (81.55–103.57)
GMT ratio (95% CI)	1.43 (1.30–1.57)	
P-value ^c	<0.0001	
GMFR (95% CI)	15.74 (14.79–16.76)	11.07 (10.08–12.15)
GMT ^b at 2 weeks after second dose (95% CI)	2850.45 (2586.51– 3141.32)	215.67 (193.52–240.36)
GMT ratio (95% CI)	13.22 (12.13–14.40)	
P-value ^c	<0.0001	
GMFR (95% CI)	296.10 (278.11–315.24)	23.02 (21.14–25.06)
Seroconversion rate (SCR)		
SCR at 4 weeks after first dose [n/N] (95% CI)	92.47% [811/877] (90.52–94.13)	84.81% [374/441] (81.11–88.03)
Difference in SCR (95% CI)	7.67 (3.89–11.44)	
P-value ^d	<0.0001	
SCR at 2 weeks after second dose [n/N] (95% CI)	99.54% [873/877] (98.84–99.88)	96.83% [427/441] (94.73–98.25)
Difference in SCR (95% CI)	2.72 (1.02–4.41)	
P-value ^d	<0.0001	

GMT ratio = GBP510/AS03 / ChAdOx1-S. Difference in SCR = GBP510/AS03 – ChAdOx1-S.

GMT = anti-logarithm [mean of natural logarithm (titre at visit n)]. GMFR = anti-logarithm [mean of natural logarithm (titre at visit n/titre at baseline)]. SCR = percentage of participants with ≥ 4 -fold rise from baseline. 95% confidence intervals for GMT and GMFR calculated using Wald method with t-distribution. 95% CI for percentage of participants with ≥ 4 -fold rise calculated using Clopper-Pearson method. 95% CI for difference between groups for participants with ≥ 4 -fold rise using Wald method.

a Between-group difference (two sample t-test).

b Post-vaccination GMT was adjusted for age group (18–64 years, ≥ 65 years) and baseline antibody level.

c ANCOVA with treatment group, age group (18–64, ≥ 65 years) as factors, and baseline antibody level as covariate.

d Between-group difference (chi-square test).

ANCOVA = analysis of covariance; CI = confidence interval; ELISA = enzyme-linked immunosorbent assay; GMFR = geometric mean fold rise; GMT = geometric mean titre; RBD = receptor-binding domain.

Table 4 Cell-mediated immune response based on FluoroSpot assay (quantification of cytokine-secreting cells) and intracellular cytokine staining (for CD4+ T cells expressing cytokines)

	GBP510/AS03				ChAdOx1-S			
FluoroSpot assay^a (median values)								
Cytokine	IFN- γ	IL-2	IL-4	TNF- α	IFN- γ	IL-2	IL-4	TNF- α
Baseline	7.00	24.00	13.00	23.00	7.00	19.50	13.00	23.00
2 weeks after second dose	20.00	57.00	13.00	52.00	15.00	27.00	13.00	47.00
Change from baseline	13.00	33.00	0.00	29.00	8.00	7.50	0.00	24.00
Intracellular cytokine staining (CD4+ cells)^b (median values)								
Cytokine	IFN- γ	IL-2	IL-4	TNF- α	IFN- γ	IL-2	IL-4	TNF- α
Baseline	0.00	0.01	0.00	0.06	0.00	0.01	0.00	0.03
2 weeks after second dose	0.01	0.06	0.00	0.23	0.00	0.02	0.00	0.09
Change from baseline	0.01	0.05	0.00	0.17	0.00	0.01	0.00	0.06

Tests were performed in pragmatically selected participants (approximately 10% of Cohort 1 participants).

a FluoroSpot assay units: SFC/ 2.5×10^5 peripheral blood mononuclear cells (PBMCs).

b Intracellular cytokine staining (ICS) units: % of RBD-specific CD4+ T cells expressing cytokines.

IFN = interferon, IL = interleukin, RBD = receptor-binding domain, TNF = tumour necrosis factor.

Table 5 Overall adverse events (after any study vaccination) up to median 2.5 months after second vaccination (safety dataset)


	GBP510/AS03 (N=3029)	ChAdOx1-S (N=996)
Immediate Unsolicited Systemic AEs (within 30 mins), n (%) [no. of AEs] Exact 95% CI	6 (0.20) [7] (0.07–0.43)	0 (0.00–0.37)
Immediate Unsolicited Systemic ADRs (within 30 mins), n (%) [no. of ADRs] Exact 95% CI	5 (0.17) [6] (0.05–0.38)	0 (0.00–0.37)
Solicited Local AEs within 7 days, n (%) [no. of AEs] Exact 95% CI	1717 (56.69) [2946] (54.90–58.46)	490 (49.20) [677] (46.05–52.35)
Solicited Systemic AEs within 7 days, n (%) [no. of AEs] Exact 95% CI	1551 (51.21) [6133] (49.41–53.00)	533 (53.51) [2067] (50.36–56.65)
Unsolicited AEs within 28 days, n (%) [no. of AEs] Exact 95% CI	402 (13.27) [640] (12.08–14.53)	145 (14.56) [213] (12.43–16.90)
Unsolicited ADRs within 28 days, n (%) [no. of ADRs] Exact 95% CI	106 (3.50) [164] (2.87–4.22)	41 (4.12) [59] (2.97–5.54)
SAEs, n (%) [no. of AEs] Exact 95% CI	25 (0.83) [25] (0.53–1.22)	8 (0.80) [11] (0.35–1.58)
AESIs, n (%) [no. of AEs] Exact 95% CI	2 (0.07) [2] (0.01–0.24)	3 (0.30) [3] (0.06–0.88)
MAAEs, n (%) [no. of AEs] Exact 95% CI	227 (7.49) [279] (6.58–8.49)	84 (8.43) [122] (6.78–10.34)
MAADRs, n (%) [no. of ADRs] Exact 95% CI	19 (0.63) [28] (0.38–0.98)	10 (1.00) [19] (0.48–1.84)
AEs leading to study withdrawal*, n (%) [no. of AEs] Exact 95% CI	3 (0.10) [8] (0.02–0.29)	2 (0.20) [4] (0.02–0.72)

Data presented as: 'number of participants (% participants) [number of events]'. Denominator of % is group N. SAEs, AESIs, MAAEs, MAADRs and death reported for whole study period.

AE = adverse event, ADR= adverse drug reaction, CI = confidence interval, SAE = serious adverse event, AESI = adverse event of special interest, MAAE = medically attended adverse event, MAADR = medically attended adverse drug reaction.

* The case checked on 'at the discretion of the investigator or sponsor due to safety concerns' as a primary reason for discontinuation and checked on 'Stop Vaccination (only if, prior to second vaccination)' as changes to IP vaccination. 95% confidence interval was calculated by Clopper-Pearson Methods.

Figure 1 Study disposition



Primary Reason for Discontinuation

- (1) At the discretion of the investigator or sponsor due to safety concerns (i.e. AE/SAEs)
 - (2) Lost to follow-up
 - (3) At the discretion of the investigator or sponsor due to significant non-compliance with the protocol (i.e. refused / major protocol deviation including newly developed or not pre-identified exclusion criteria are met)
 - (4) At request of the participant
 - (5) Death
 - (6) Pregnancy
 - (7) Study termination by sponsor
 - (8) Others
- * FAS = Full Analysis Set, PPS 1 = per-protocol set 1

Figure 2 Boxplots and individual data for the natural logarithmic titre by live virus neutralisation assay at baseline (visit 2), 4 weeks after first vaccination (visit 4), and 2 weeks after second vaccination (visit 6) (per-protocol set)






Figure 3 Incidence rates for solicited local (A) and systemic (B) adverse events within 7 days after each-dose vaccination


After first dose (A-1)




After first dose (B-1)




After second dose (A-2)




After second dose (B-2)



After any dose (A-3)



After any dose (B-3)



The severity of adverse events was based on the US Food and Drug Administration toxicity grading scale for healthy volunteers enrolled in preventive vaccine clinical trials.⁹ All solicited local and systemic adverse events were considered related to the study intervention

Supplementary Appendix

Supplement to: Cheong, et al. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: randomised, active-controlled, observer-blinded, phase 3 trial

Table of Contents

I. Supplementary Tables

- Table S1. Adverse Events of Special Interest (AESI) Relevant to COVID-19
- Table S2. Potential Immune-Mediated Diseases Included as Adverse Events of Special Interest
- Table S3. Immunogenicity Assessment by Live Virus Neutralisation Assays (FRNT): Age Group 18-64 Years (Per-Protocol Set)
- Table S4. Immunogenicity Assessment by Live Virus Neutralisation Assays (FRNT): Age Group ≥ 65 Years (Per-Protocol Set)
- Table S5. The Consistency Among Ethnicities by Live Virus Neutralisation Assay (FRNT) (Per Protocol Set)
- Table S6. Immunogenicity Assessment by Live Virus Neutralization Assays (FRNT50) against Delta (Per-Protocol Set 1)
- Table S7. Immunogenicity Assessment by Live Virus Neutralizing Assays (FRNT50) against Omicron BA.1 (Per-Protocol Set 1)
- Table S8. Immunogenicity Assessment by Live Virus Neutralizing Assays (FRNT50) against Omicron BA. 5 (Per-Protocol Set 1)
- Table S9. Cell-mediated Response: CD8+ T cell at Visit 6 (Per-Protocol Set 1)
- Table S10. Solicited Local AE by Maximum severity [after any vaccination] (Safety Set)
- Table S11. Solicited Systemic AEs by Maximum Severity [after any vaccination] (Safety Set)
- Table S12. Unsolicited AE [after any vaccination] (Safety Set)
- Table S13. Virologically-confirmed COVID-19 Observed within a Median 2.5-Months of Follow-up after 2nd Vaccination (Safety Set)
- Table S14. Virologically-suspected COVID-19 Observed within a Median 2.5-Months of Follow-up after 2nd Vaccination (Safety set)

II. Supplementary Figures

- Figure S1. Schema of Study Enrolment
- Figure S2. Analysis Sets
- Figure S3. Boxplot for the Natural Logarithmic of Titre by ELISA at Visit 2, 4, and 6 (Per-Protocol Set 1)
- Figure S4. Cell-mediated Response FluoroSpot Assay Per-Protocol Set 1 [T cell: IFN γ]
- Figure S5. Cell-mediated Response FluoroSpot Assay Per-Protocol Set 1 [T cell: IL-2]
- Figure S6. Cell-mediated Response FluoroSpot Assay Per-Protocol Set 1 [T cell: TNF α]
- Figure S7. Cell-mediated Response FluoroSpot Assay Per-Protocol Set 1 [T cell: IL-4]
- Figure S8. Cell-mediated Response FACS Per-Protocol Set 1 [CD4+ T cell: IFN γ]
- Figure S9. Cell-mediated Response FACS Per-Protocol Set 1 [CD4+ T cell: IL-2]
- Figure S10. Cell-mediated Response FACS Per-Protocol Set 1 [CD4+ T cell: TNF α]
- Figure S11. Cell-mediated Response FACS Per-Protocol Set 1 [CD4+ T cell: IL-4]

III. Supplementary Authors List

I. Supplementary Tables

Table S1 Adverse events of special interest (AESI) relevant to COVID-19

AESI included because they are seen with COVID-19 Disease ^{3,4}
Acute respiratory distress syndrome
Multisystem inflammatory syndrome (children & adults)
Acute cardiovascular injury (includes: myocarditis/pericarditis, microangiopathy, heart failure, stress cardiomyopathy, coronary artery disease arrhythmia)
Coagulation disorder (includes: thrombotic disorders, bleeding disorders)
Anosmia, ageusia
Chilblain – like lesions
Erythema multiforme
Single Organ Cutaneous Vasculitis
Acute kidney injury
Acute liver injury
Acute pancreatitis
Rhabdomyolysis
Subacute thyroiditis
AESI included because they have a proven or theoretical association with immunization in general
Anaphylaxis ^{1,2}
Thrombocytopenia ^{1,2,3,4}
Generalized convulsion ^{1,2}
Acute disseminated encephalomyelitis ⁴
Guillain Barré Syndrome ^{3,4}
AESI included because they have a proven or theoretical association with specific vaccine platform(s)
Acute aseptic arthritis ^{r-VSV}
Aseptic meningitis ^{Live vaccines}
Encephalitis / Encephalomyelitis ^{Live vaccines}
Idiopathic Peripheral Facial Nerve Palsy ^{Intranasal E. coli Heat Labile Toxin Adjuvanted Vaccine}
Vaccine associated enhanced disease ^{1(Formalin inactivated measles/RSV; HIV), 2(Chimeric YF Dengue), 5 (SARS/MERS-CoVs)}
Thrombosis with thrombocytopenia syndrome ^{Recombinant adenoviral vector vaccines}

¹ Proven association with immunization encompassing several different vaccines

² Proven association with vaccine that could theoretically be true for novel COVID-19 vaccines

³ Theoretical concern based on wild type disease immunopathogenesis

⁴ Theoretical concern related to viral replication during wild type disease

⁵ Theoretical concern because it has been demonstrated in an animal model with ≥ 1 vaccine platform

Table S2 Potential immune-mediated diseases included as adverse events of special interest

Medical Concept	Additional Notes
Blood disorders and coagulopathies	
Antiphospholipid syndrome	
Autoimmune anemia aplastic	
Autoimmune anemia hemolytic	<ul style="list-style-type: none"> Includes warm antibody hemolytic anemia and cold antibody hemolytic anemia
Autoimmune lymphoproliferative syndrome (ALPS)	
Autoimmune neutropenia	
Autoimmune pancytopenia	
Autoimmune thrombocytopenia	<ul style="list-style-type: none"> Frequently used related terms include: “autoimmune thrombocytopenic purpura”, “idiopathic thrombocytopenic purpura (ITP)”, “idiopathic immune thrombocytopenia”, “primary immune thrombocytopenia”.
Evans syndrome	
Pernicious anemia	
Thrombosis with thrombocytopenia syndrome (TTS)	
Thrombotic thrombocytopenic purpura	<ul style="list-style-type: none"> Also known as “Moscowitz-syndrome” or “microangiopathic hemolytic anemia”
Cardio-pulmonary inflammatory disorders	
Idiopathic Myocarditis/Pericarditis	<p>Including but not limited to:</p> <ul style="list-style-type: none"> Autoimmune / Immune-mediated myocarditis Autoimmune / Immune-mediated pericarditis Giant cell myocarditis
Idiopathic fibrosis pulmonary	<p>Including but not limited to:</p> <ul style="list-style-type: none"> Idiopathic interstitial pneumonia (frequently used related terms include “Interstitial lung disease”, “Pulmonary fibrosis”, “Immune-mediated pneumonitis”) Pleuroparenchymal fibroelastosis (PPFE)
Pulmonary alveolar proteinosis (PAP)	<ul style="list-style-type: none"> Frequently used related terms include: “pulmonary alveolar lipoproteinosis”, “phospholipidosis”
Endocrine disorders	
Addison’s disease	
Autoimmune /Immune- mediated thyroiditis	<p>Including but not limited to:</p> <ul style="list-style-type: none"> Hashimoto thyroiditis (autoimmune hypothyroidism, lymphocytic thyroiditis) Atrophic thyroiditis Silent thyroiditis Thyrotoxicosis

Autoimmune diseases of the testis and ovary	<ul style="list-style-type: none"> Includes autoimmune oophoritis, autoimmune ovarian failure and autoimmune orchitis
Autoimmune hyperlipidemia	
Autoimmune hypophysitis	
Diabetes mellitus type I	
Grave's or Basedow's disease	<ul style="list-style-type: none"> Includes Marine Lenhart syndrome and Graves' ophthalmopathy, also known as thyroid eye disease (TED) or endocrine ophthalmopathy
Insulin autoimmune syndrome	
Polyglandular autoimmune syndrome	<ul style="list-style-type: none"> Includes Polyglandular autoimmune syndrome type I, II and III
Eye disorders	
Ocular Autoimmune / Immune-mediated disorders	<p>Including but not limited to:</p> <ul style="list-style-type: none"> Acute macular neuroretinopathy (also known as acute macular outer retinopathy) Autoimmune / Immune-mediated retinopathy Autoimmune / Immune-mediated uveitis, including idiopathic uveitis and sympathetic ophthalmia Cogan's syndrome: an oculo-audiovestibular disease Ocular pemphigoid Ulcerative keratitis Vogt-Koyanagi-Harada disease
Gastrointestinal disorders	
Autoimmune/Immune-mediated pancreatitis	
Celiac disease	
Inflammatory bowel disease	<p>Including but not limited to:</p> <ul style="list-style-type: none"> Crohn's disease Microscopic colitis Terminal ileitis Ulcerative colitis Ulcerative proctitis
Hepatobiliary disorders	
Autoimmune cholangitis	
Autoimmune hepatitis	
Primary biliary cirrhosis	
Primary sclerosing cholangitis	
Musculoskeletal and connective tissue disorders	
Gout	<ul style="list-style-type: none"> Includes gouty arthritis

Idiopathic inflammatory myopathies	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Dermatomyositis ● Inclusion body myositis ● Immune-mediated necrotizing myopathy ● Polymyositis
Mixed connective tissue disorder	
Polymyalgia rheumatica (PMR)	
Psoriatic arthritis (PsA)	
Relapsing polychondritis	
Rheumatoid arthritis	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Rheumatoid arthritis associated conditions ● Juvenile idiopathic arthritis ● Palindromic rheumatism ● Still's disease ● Felty's syndrome
Sjögren's syndrome	
Spondyloarthritis	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Ankylosing spondylitis ● Juvenile spondyloarthritis ● Keratoderma blenorrhagica ● Psoriatic spondylitis ● Reactive Arthritis (Reiter's Syndrome) ● Undifferentiated spondyloarthritis
Systemic Lupus Erythematosus	<ul style="list-style-type: none"> ● Includes Lupus associated conditions (e.g. Cutaneous lupus erythematosus, Lupus nephritis, etc.) or complications such as shrinking lung syndrome (SLS)
Systemic Scleroderma (Systemic Sclerosis)	<ul style="list-style-type: none"> ● Includes Reynolds syndrome (RS), systemic sclerosis with diffuse scleroderma and systemic sclerosis with limited scleroderma (also known as CREST syndrome)
Neuroinflammatory/neuromuscular disorders	
Acute disseminated encephalomyelitis (ADEM) and other inflammatory- demyelinating variants	<p>Includes the following:</p> <ul style="list-style-type: none"> ● Acute necrotising myelitis ● Bickerstaff's brainstem encephalitis ● Disseminated necrotizing leukoencephalopathy (also known as Weston-Hurst syndrome, acute hemorrhagic leuko- encephalitis, or acute necrotizing hemorrhagic encephalomyelitis) ● Myelin oligodendrocyte glycoprotein antibody-associated disease ● Neuromyelitis optica (also known as Devic's disease) ● Noninfective encephalitis / encephalomyelitis / myelitis ● Postimmunization encephalomyelitis
Guillain-Barré syndrome (GBS)	<ul style="list-style-type: none"> ● Includes variants such as Miller Fisher syndrome and the acute motor and sensory axonal neuropathy (AMSAN)

Idiopathic cranial nerve palsies/paresis and inflammations (neuritis)	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Cranial nerve neuritis (e.g. Optic neuritis) ● Idiopathic nerve palsies/paresis (e.g. Bell’s palsy) ● Melkersson-Rosenthal syndrome ● Multiple cranial nerve palsies/paresis
Multiple Sclerosis (MS)	<p>Includes the following:</p> <ul style="list-style-type: none"> ● Clinically isolated syndrome (CIS) ● Malignant MS (the Marburg type of MS) ● Primary-progressive MS (PPMS) ● Radiologically isolated syndrome (RIS) ● Relapsing-remitting MS (RRMS) ● Secondary-progressive MS (SPMS) ● Uhthoff’s phenomenon
Myasthenia gravis	<ul style="list-style-type: none"> ● Includes ocular myasthenia and Lambert-Eaton myasthenic syndrome
Narcolepsy	<ul style="list-style-type: none"> ● Includes narcolepsy with or without presence of unambiguous cataplexy
Peripheral inflammatory demyelinating neuropathies and plexopathies	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Acute Brachial Radiculitis (also known as Parsonage-Turner Syndrome or neuralgic amyotrophy) ● Antibody-mediated demyelinating neuropathy ● Chronic idiopathic axonal polyneuropathy (CIAP) ● Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), including atypical CIDP variants (e.g. multifocal acquired demyelinating sensory and motor neuropathy also known as Lewis-Sumner syndrome) ● Multifocal motor neuropathy (MMN)
Transverse myelitis (TM)	<ul style="list-style-type: none"> ● Includes acute partial transverse myelitis (APTМ) and acute complete transverse myelitis (ACTM)
Renal disorders	
Autoimmune / Immune- mediated glomerulonephritis	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● IgA nephropathy ● IgM nephropathy ● C1q nephropathy ● Fibrillary glomerulonephritis ● Glomerulonephritis rapidly progressive ● Membranoproliferative glomerulonephritis ● Membranous glomerulonephritis ● Mesangioproliferative glomerulonephritis ● Tubulointerstitial nephritis and uveitis syndrome
Skin and subcutaneous tissue disorders	
Alopecia areata	

Autoimmune / Immune- mediated blistering dermatoses	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Bullous Dermatitis ● Bullous Pemphigoid ● Dermatitis herpetiformis ● Epidermolysis bullosa acquisita (EBA) ● Linear IgA-mediated bullous dermatosis (LABD), also known as Linear IgA disease ● Pemphigus
Erythema multiforme	
Erythema nodosum	
Reactive granulomatous dermatitis	<p>Including but not limited to</p> <ul style="list-style-type: none"> ● Interstitial granulomatous dermatitis ● Palisaded neutrophilic granulomatous dermatitis
Lichen planus	<ul style="list-style-type: none"> ● Includes liquen planopilaris
Localised Scleroderma (Morphoea)	<ul style="list-style-type: none"> ● Includes Eosinophilic fasciitis (also called Shulman syndrome)
Psoriasis	
Pyoderma gangrenosum	
Stevens-Johnson Syndrome (SJS)	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Toxic Epidermal Necrolysis (TEN) ● SJS-TEN overlap
Sweet's syndrome	<ul style="list-style-type: none"> ● Includes Acute febrile neutrophilic dermatosis
Vitiligo	
Vasculitis	
Large vessels vasculitis	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Arteritic anterior ischemic optic neuropathy (AAION or arteritic AION) ● Giant cell arteritis (also called temporal arteritis) ● Takayasu's arteritis

Medium sized and/or small vessels vasculitis	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Anti-neutrophil cytoplasmic antibody (ANCA) positive vasculitis (type unspecified) ● Behcet's syndrome ● Buerger's disease (thromboangiitis obliterans) ● Churg–Strauss syndrome (allergic granulomatous angiitis) ● Erythema induratum (also known as nodular vasculitis) ● Henoch-Schonlein purpura (also known as IgA vasculitis) ● Microscopic polyangiitis ● Necrotizing vasculitis ● Polyarteritis nodosa ● Single organ cutaneous vasculitis, including leukocytoclastic vasculitis, hypersensitivity vasculitis and acute hemorrhagic edema of infancy (AHEI) ● Wegener's granulomatosis
Other (including multisystemic)	
Anti-synthetase syndrome	
Capillary leak syndrome	<ul style="list-style-type: none"> ● Frequently used related terms include : “systemic capillary leak syndrome (SCLS)” or “Clarkson's Syndrome”
Goodpasture syndrome	<ul style="list-style-type: none"> ● Frequently used related terms include : “pulmonary renal syndrome” and “anti-Glomerular Basement Membrane disease (anti-GBM disease)”
Immune-mediated enhancement of disease	<ul style="list-style-type: none"> ● Includes vaccine associated enhanced disease (VAED and VAERD). Frequently used related terms include “vaccine- mediated enhanced disease (VMED)”, “enhanced respiratory disease (ERD)”, “vaccine-induced enhancement of
	infection”, “disease enhancement”, “immune enhancement”, and “antibody-dependent enhancement (ADE)
Immunoglobulin G4 related disease	
Langerhans' cell histiocytosis	
Multisystem inflammatory syndromes	<p>Including but not limited to:</p> <ul style="list-style-type: none"> ● Kawasaki's disease ● Multisystem inflammatory syndrome in adults (MIS-A) ● Multisystem inflammatory syndrome in children (MIS-C)
Overlap syndrome	
Raynaud's phenomenon	
Sarcoidosis	<ul style="list-style-type: none"> ● Includes Lofegren syndrome
Susac's syndrome	

Table S3 Immunogenicity Assessment by Live Virus Neutralisation Assays (FRNT): Age Group 18-64 Years (Per-Protocol Set)

	GBP510 (N=834)	ChAdOx1-S (N=417)
Baseline		
n	834	417
GMT(SD)	8.17(1.08)	8.13(1.06)
95% Confidence Interval	[8.13, 8.22]	[8.09, 8.18]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	1.01(NA)	
95% Confidence Interval	[1.00, 1.01]	
P-value [1]	0.1720	
Visit 4 (4 weeks after 1st vaccination)		
n	187	88
GMT(SD)	11.49(2.28)	40.74(3.56)
95% Confidence Interval	[10.20, 12.94]	[31.14, 53.30]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	0.28(NA)	
95% Confidence Interval	[0.21, 0.38]	
P-value [1]	<0.0001	
GMFR(SD)	1.41(2.28)	5.02(3.51)
95% Confidence Interval	[1.26, 1.59]	[3.85, 6.54]
Adjusted GMT(SE)†	11.48(1.07)	40.79(1.11)
95% Confidence Interval	[9.97, 13.22]	[33.22, 50.10]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	0.28(1.13)	
95% Confidence Interval	[0.22, 0.36]	
P-value [2]	<0.0001	
Adjusted GMT(SE)‡	9.98(1.15)	35.51(1.18)
95% Confidence Interval	[7.55, 13.20]	[25.82, 48.82]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	0.28(1.14)	
95% Confidence Interval	[0.22, 0.36]	
P-value [3]	<0.0001	
Participants with ≥ 4-fold rise, n(%)	11(5.88)	49(55.68)
95% Confidence Interval	[2.97, 10.28]	[44.70, 66.27]
Difference in Proportions of the Participant with ≥ 4-fold rise	-49.80	
95% Confidence Interval	[-60.85, -38.58]	
P-value [4]	<0.0001 (c)	
Visit 6 (2 weeks after 2nd vaccination)		
n	834	417
GMT(SD)	304.52(2.48)	103.01(2.72)
95% Confidence Interval	[286.29, 323.92]	[93.56, 113.40]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	2.96(NA)	
95% Confidence Interval	[2.64, 3.31]	
P-value [1]	<0.0001	
GMFR(SD)	37.26(2.48)	12.67(2.72)
95% Confidence Interval	[35.03, 39.63]	[11.51, 13.95]
Adjusted GMT(SE)†	304.31(1.03)	103.15(1.05)
95% Confidence Interval	[285.49, 324.37]	[94.24, 112.90]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	2.95(1.06)	

	GBP510 (N=834)	ChAdOx1-S (N=417)
95% Confidence Interval	[2.64, 3.30]	
P-value [2]	<0.0001	
Adjusted GMT(SE)‡	248.59(1.07)	83.82(1.08)
95% Confidence Interval	[218.85, 282.37]	[72.68, 96.67]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	2.97(1.06)	
95% Confidence Interval	[2.66, 3.31]	
P-value [3]	<0.0001	
Participants with ≥ 4-fold rise, n(%)	819(98.20)	366(87.77)
95% Confidence Interval	[97.05, 98.99]	[84.23, 90.76]
Difference in Proportions of the Participant with ≥ 4-fold rise	10.43	
95% Confidence Interval	[7.35, 14.06]	
P-value [4]	<0.0001 (c)	

GMT = geometric mean titer, SD = standard deviation, SE = standard error, GMFR = geometric mean fold rise, ANCOVA = analysis of covariance, NA = not applicable.

Assay unit: IU/mL

[1] Testing for difference between treatment groups (two sample t-test).

[2] † ANCOVA model with treatment group as a factor, and baseline antibody level as covariate.

[3] ‡ ANCOVA model with treatment group, sex, race as factors and baseline antibody level as covariate.

[4] § Testing for difference between treatment groups (chi-square test (c) or Fisher's exact test (f)).

GMT = anti-logarithm[mean of natural logarithm(titer at visit n)], GMFR = anti-logarithm[mean of natural logarithm(titer at visit n/titer at visit 2)].

The test result was collected for randomly selected participants (about 20% of all participants) at Visit 4.

When two samples had unequal variance, the standard deviation for the ratio of GMT is presented 'NA'.

Due to infinite likelihood problem, the variance model for adjusted GMT was fitted under the assumption of homoscedasticity.

95% confidence intervals for GMT and GMFR are calculated using Wald method with t-distribution.

The 95% CI of percentage of participants ≥ 4-fold rises was calculated based on Clopper-Pearson method.

The 95% CI of the difference between groups was calculated based on Chan and Zhang method.

Table S4 Immunogenicity Assessment by Live Virus Neutralisation Assays (FRNT): Age Group ≥ 65 Years (Per-Protocol Set)

	GBP510 (N=43)	ChAdOx1-S (N=24)
Baseline		
n	43	24
GMT(SD)	8.29(1.13)	8.08(1.00)
95% Confidence Interval	[7.99, 8.60]	[8.08, 8.08]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	1.03(NA)	
95% Confidence Interval	[0.99, 1.06]	
P-value [1]	0.1617	
Visit 4 (4 weeks after 1st vaccination)		
n	8	8
GMT(SD)	8.08(1.00)	49.81(2.55)
95% Confidence Interval	[8.08, 8.08]	[22.78, 108.92]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	0.16(NA)	
95% Confidence Interval	[0.07, 0.35]	
P-value [1]	0.0009	
GMFR(SD)	1.00(1.00)	6.17(2.55)
95% Confidence Interval	[1.00, 1.00]	[2.82, 13.48]
Adjusted GMT(SE)†	8.08(1.26)	49.81(1.26)
95% Confidence Interval	[4.89, 13.35]	[30.16, 82.27]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	0.16(1.39)	
95% Confidence Interval	[0.08, 0.33]	
P-value [2]	<0.0001	
Adjusted GMT(SE)‡	11.55(1.56)	65.34(1.45)
95% Confidence Interval	[4.40, 30.35]	[29.02, 147.11]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	0.18(1.43)	
95% Confidence Interval	[0.08, 0.38]	
P-value [3]	0.0004	
Participants with ≥ 4 -fold rise, n(%)	0(0.00)	5(62.50)
95% Confidence Interval	[0.00, 36.94]	[24.49, 91.48]
Difference in Proportions of the Participant with ≥ 4 -fold rise	-62.50	
95% Confidence Interval	[-91.48, -17.29]	
P-value [4]	0.0256 (f)	
Visit 6 (2 weeks after 2nd vaccination)		
n	43	24
GMT(SD)	234.69(3.57)	89.29(3.56)
95% Confidence Interval	[158.63, 347.21]	[52.24, 152.62]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	2.63(3.57)	
95% Confidence Interval	[1.38, 5.02]	
P-value [1]	0.0040	
GMFR(SD)	28.31(3.65)	11.05(3.56)
95% Confidence Interval	[19.01, 42.16]	[6.47, 18.89]
Adjusted GMT(SE)†	235.83(1.21)	87.27(1.30)

	GBP510 (N=43)	ChAdOx1-S (N=24)
95% Confidence Interval	[159.97, 347.66]	[51.71, 147.28]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	2.70(1.39)	
95% Confidence Interval	[1.40, 5.22]	
P-value [2]	0.0036	
Adjusted GMT(SE)‡	144.12(1.36)	53.99(1.41)
95% Confidence Interval	[77.99, 266.32]	[27.04, 107.79]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	2.67(1.37)	
95% Confidence Interval	[1.42, 5.01]	
P-value [3]	0.0027	
Participants with ≥ 4-fold rise, n(%)	41(95.35)	19(79.17)
95% Confidence Interval	[84.19, 99.43]	[57.85, 92.87]
Difference in Proportions of the Participant with ≥ 4-fold rise	16.18	
95% Confidence Interval	[-0.51, 37.57]	
P-value [4]	0.0882 (f)	

GMT = geometric mean titer, SD = standard deviation, SE = standard error, GMFR = geometric mean fold rise, ANCOVA = analysis of covariance, NA = not applicable.

Assay unit: IU/mL

[1] Testing for difference between treatment groups (two sample t-test).

[2] † ANCOVA model with treatment group as a factor, and baseline antibody level as covariate.

[3] ‡ ANCOVA model with treatment group, sex, race as factors and baseline antibody level as covariate.

[4] Testing for difference between treatment groups (chi-square test (c) or Fisher's exact test (f)).

GMT = anti-logarithm[mean of natural logarithm(titer at visit n)], GMFR = anti-logarithm[mean of natural logarithm(titer at visit n/titer at visit 2)].

The test result was collected for randomly selected participants (about 20% of all participants) at Visit 4.

When two samples had unequal variance, the standard deviation for the ratio of GMT is presented 'NA'.

95% confidence intervals for GMT and GMFR are calculated using Wald method with t-distribution.

The 95% CI of percentage of participants ≥ 4-fold rises was calculated based on Clopper-Pearson method.

The 95% CI of the difference between groups was calculated based on Chan and Zhang method.

Table S5 The Consistency Among Ethnicities by Live Virus Neutralisation Assay (FRNT) (Per Protocol Set)

	Korean		Southeast Asian		Caucasian	
	GBP510 (N=303)	ChAdOx1-S (N=154)	GBP510 (N=529)	ChAdOx1-S (N=266)	GBP510 (N=45)	ChAdOx1-S (N=21)
Baseline						
n	303	154	529	266	45	21
GMT(SD)	8.20(1.09)	8.14(1.07)	8.16(1.08)	8.12(1.05)	8.24(1.10)	8.08(1.00)
95% Confidence Interval	[8.12, 8.28]	[8.06, 8.23]	[8.11, 8.21]	[8.07, 8.17]	[8.01, 8.47]	[8.08, 8.08]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	1.01(NA)		1.00(NA)		1.02(NA)	
95% Confidence Interval	[0.99, 1.02]		[1.00, 1.01]		[0.99, 1.05]	
P-value [1]	0.3169		0.2992		0.1597	
Visit 6 (2 weeks after 2nd vaccination)						
n	303	154	529	266	45	21
GMT(SD)	306.47(2.17)	75.26(2.54)	305.79(2.68)	131.12(2.67)	216.59(3.23)	41.12(2.48)
95% Confidence Interval	[280.82, 334.47]	[64.89, 87.29]	[281.12, 332.62]	[116.48, 147.60]	[152.29, 308.04]	[27.17, 62.21]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	4.07(NA)		2.33(2.67)		5.27(3.00)	
95% Confidence Interval	[3.43, 4.84]		[2.02, 2.70]		[2.95, 9.40]	
P-value [1]	<0.0001		<0.0001		<0.0001	
GMFR(SD)	37.38(2.17)	9.25(2.54)	37.47(2.68)	16.14(2.67)	26.28(3.31)	5.09(2.48)
95% Confidence Interval	[34.24, 40.80]	[7.97, 10.72]	[34.44, 40.76]	[14.34, 18.17]	[18.34, 37.67]	[3.36, 7.70]
Adjusted GMT(SE)†	528.33(1.27)	129.88(1.28)	268.71(1.07)	115.88(1.09)	154.40(1.62)	28.11(1.65)
95% Confidence Interval	[328.71, 849.20]	[80.10, 210.62]	[233.68, 308.99]	[98.64, 136.12]	[59.19, 402.80]	[10.32, 76.60]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	4.07(1.08)		2.32(1.08)		5.49(1.31)	
95% Confidence Interval	[3.47, 4.77]		[2.01, 2.68]		[3.21, 9.38]	
P-value [2]	<0.0001		<0.0001		<0.0001	
Ratio of GMTs > 1	Yes		Yes		Yes	
Adjusted GMT(SE)‡	522.57(1.28)	128.49(1.28)	270.12(1.07)	115.96(1.09)	144.68(1.36)	27.77(1.41)
95% Confidence Interval	[324.01, 842.80]	[78.97, 209.07]	[234.87, 310.65]	[98.72, 136.21]	[77.66, 269.53]	[14.06, 54.83]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SE)	4.07(1.09)		2.33(1.08)		5.21(1.31)	
95% Confidence Interval	[3.46, 4.77]		[2.02, 2.69]		[3.05, 8.91]	
P-value [3]	<0.0001		<0.0001		<0.0001	

	Korean		Southeast Asian		Caucasian	
	GBP510 (N=303)	ChAdOx1-S (N=154)	GBP510 (N=529)	ChAdOx1-S (N=266)	GBP510 (N=45)	ChAdOx1-S (N=21)
Participants with \geq 4-fold rise, n(%)	301(99.34)	124(80.52)	518(97.92)	249(93.61)	41(91.11)	12(57.14)
95% Confidence Interval	[97.64, 99.92]	[73.37, 86.45]	[96.31, 98.96]	[89.96, 96.23]	[78.78, 97.52]	[34.02, 78.18]
Difference in Proportions of the Participant with \geq 4-fold rise	18.82		4.31		33.97	
95% Confidence Interval	[12.50, 25.14]		[1.13, 7.49]		[11.23, 56.71]	
P-value [4]	<0.0001 (c)		0.0019 (c)		0.0024 (f)	
Difference in Proportions of the Participant with \geq 4-fold rise > -5%	Yes		Yes		Yes	

GMT = geometric mean titer, SD = standard deviation, SE = standard error, GMFR = geometric mean fold rise, ANCOVA = analysis of covariance, NA = not applicable.

Assay unit: IU/mL

[1] Testing for between-treatment groups (two sample t-test).

[2] † ANCOVA model with treatment group, age group (18~64, \geq 65) as factors, and baseline antibody level as covariate.

[3] ‡ ANCOVA model with treatment group, age group (18~64, \geq 65), sex as factors and baseline antibody level as covariate.

[4] Testing for difference between treatment groups (chi-square test (c) or Fisher's exact test (f)).

GMT = anti-logarithm[mean of natural logarithm(titer at Visit n)], GMFR = anti-logarithm[mean of natural logarithm(titer at visit n/titer at visit 2)].

When two samples had unequal variance, the standard deviation for the ratio of GMT is presented 'NA'.

95% confidence interval for GMT and GMFR are calculated using t-distribution and Confidence Interval of Seroconversion rate is calculated using Wald method.

95% confidence interval for the percentage of participants \geq 4-fold rises was calculated by Clopper-Pearson Methods.

The 95% CI of difference in percentage of participants \geq 4-fold rises between groups was calculated based on Wald method.

Table S6 Immunogenicity Assessment by Live Virus Neutralization Assays (FRNT50) against Delta (Per-Protocol Set 1)

	GBP510 (N=877)	ChAdOx1-S (N=441)
Visit 6 (2 weeks after 2nd vaccination)		
n	137	68
GMT(SD)	2644.26(2.47)	96.96(4.01)
95% Confidence Interval	[2269.54, 3080.84]	[69.29, 135.67]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	27.27(NA)	
95% Confidence Interval	[18.88, 39.39]	
P-value [1]	<0.0001	

GMT = geometric mean titer, SD = standard deviation, NA = not applicable.

GMT = anti-logarithm[mean of natural logarithm(titer at visit n)].

The test result was collected for randomly selected participants (about 10% of all participants).

[1] Testing for between-treatment groups (two sample t-test).

When two samples had unequal variance, the standard deviation for the ratio of GMT is presented 'NA'.

95% confidence intervals for GMT are calculated using Wald method with t-distribution.

Table S7 Immunogenicity Assessment by Live Virus Neutralizing Assays (FRNT50) against Omicron BA.1 (Per-Protocol Set 1)

	GBP510 (N=877)	ChAdOx1-S (N=441)
Visit 6 (2 weeks after 2nd vaccination)		
n	137	68
GMT(SD)	129.09(2.98)	12.27(2.05)
95% Confidence Interval	[107.36, 155.22]	[10.32, 14.59]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	10.52(NA)	
95% Confidence Interval	[8.18, 13.53]	
P-value [1]	<0.0001	

GMT = geometric mean titer, SD = standard deviation, NA = not applicable.

GMT = anti-logarithm[mean of natural logarithm(titer at visit n)].

The test result was collected for randomly selected participants (about 10% of all participants).

[1] Testing for between-treatment groups (two sample t-test).

When two samples had unequal variance, the standard deviation for the ratio of GMT is presented 'NA'.

95% confidence intervals for GMT are calculated using Wald method with t-distribution.

Table S8 Immunogenicity Assessment by Live Virus Neutralizing Assays (FRNT50) against Omicron BA.5 (Per-Protocol Set 1)

	GBP510 (N=877)	ChAdOx1-S (N=441)
Visit 6 (2 weeks after 2nd vaccination)		
n	137	68
GMT(SD)	61.61(2.84)	13.56(2.19)
95% Confidence Interval	[51.64, 73.51]	[11.21, 16.40]
Ratio of GMTs (GBP510 / ChAdOx1-S)(SD)	4.54(NA)	
95% Confidence Interval	[3.51, 5.88]	
P-value [1]	<0.0001	

GMT = geometric mean titer, SD = standard deviation, NA = not applicable.

GMT = anti-logarithm[mean of natural logarithm(titer at visit n)].

The test result was collected for randomly selected participants (about 10% of all participants).

[1] Testing for between-treatment groups (two sample t-test).

When two samples had unequal variance, the standard deviation for the ratio of GMT is presented 'NA'.

95% confidence intervals for GMT are calculated using Wald method with t-distribution.

Table S9 Cell-mediated Response: CD8+ T cell at Visit 6 (Per-Protocol Set 1)

	GBP510 (N=877)	ChAdOx1-S (N=441)
[cytokines: IFNγ]		
Baseline		
n	70	36
Mean(SD)	0.00(0.01)	0.00(0.00)
Median	0.00	0.00
Min, Max	0.00, 0.05	0.00, 0.02
P-value [1]	0.3052	
n	24	10
Geometric Mean(SD)	0.01(1.86)	0.01(1.60)
95% Confidence Interval	[0.01, 0.01]	[0.01, 0.01]
P-value [1]	0.7495	
Visit 6 (2 weeks after 2nd vaccination)		
n	68	33
Mean(SD)	0.01(0.02)	0.01(0.01)
Median	0.00	0.01
Min, Max	0.00, 0.15	0.00, 0.06
P-value [1]	0.8398	
n	22	18
Geometric Mean(SD)	0.01(2.79)	0.01(1.96)
95% Confidence Interval	[0.01, 0.02]	[0.01, 0.01]
P-value [1]	0.3523	
[cytokines: IL-2]		
Baseline		
n	70	36
Mean(SD)	0.00(0.01)	0.00(0.01)
Median	0.00	0.00
Min, Max	0.00, 0.05	0.00, 0.06
P-value [1]	0.6094	
n	25	7
Geometric Mean(SD)	0.01(2.01)	0.01(2.71)
95% Confidence Interval	[0.01, 0.01]	[0.00, 0.02]
P-value [1]	0.8245	
Visit 6 (2 weeks after 2nd vaccination)		
n	68	33
Mean(SD)	0.00(0.01)	0.01(0.01)
Median	0.00	0.00
Min, Max	0.00, 0.08	0.00, 0.03
P-value [1]	0.4842	
n	20	15
Geometric Mean(SD)	0.01(2.05)	0.01(2.03)
95% Confidence Interval	[0.01, 0.02]	[0.01, 0.02]
P-value [1]	0.7884	
[cytokines: IL-4]		
Baseline		
n	70	36
Mean(SD)	0.01(0.01)	0.01(0.01)
Median	0.00	0.00
Min, Max	0.00, 0.07	0.00, 0.04
P-value [1]	0.9768	
n	24	11
Geometric Mean(SD)	0.01(2.12)	0.01(2.11)

	GBP510 (N=877)	ChAdOx1-S (N=441)
95% Confidence Interval	[0.01, 0.01]	[0.01, 0.02]
P-value [1]	0.4107	
Visit 6 (2 weeks after 2nd vaccination)		
n	68	33
Mean(SD)	0.01(0.01)	0.00(0.01)
Median	0.00	0.00
Min, Max	0.00, 0.06	0.00, 0.03
P-value [1]	0.4652	
n	29	11
Geometric Mean(SD)	0.01(1.81)	0.01(1.92)
95% Confidence Interval	[0.01, 0.01]	[0.01, 0.02]
P-value [1]	0.8626	
[cytokines: TNFα]		
Baseline		
n	70	36
Mean(SD)	0.04(0.12)	0.04(0.12)
Median	0.02	0.02
Min, Max	0.00, 0.88	0.00, 0.73
P-value [1]	0.9816	
n	45	22
Geometric Mean(SD)	0.03(3.14)	0.03(2.77)
95% Confidence Interval	[0.02, 0.04]	[0.02, 0.05]
P-value [1]	0.6388	
Visit 6 (2 weeks after 2nd vaccination)		
n	68	33
Mean(SD)	0.11(0.26)	0.07(0.13)
Median	0.02	0.02
Min, Max	0.00, 1.66	0.00, 0.57
P-value [1]	0.2742	
n	41	24
Geometric Mean(SD)	0.08(3.81)	0.04(4.34)
95% Confidence Interval	[0.05, 0.12]	[0.02, 0.07]
P-value [1]	0.0419	

SD = standard deviation, Min = minimum, Max = maximum, CMI = cell mediated immunity.

Assay unit: % of RBD-specific CD8+ T cells

[1] Testing for difference between treatment groups (two sample t-test).

The test result was collected for randomly selected participants (about 10% of all participants).

Geometric Mean = anti-logarithm[mean of natural logarithm(percentage of RBD-specific CD8+ T-cell at visit n)].

The 95% confidence intervals for Geometric Mean are calculated using Wald method with t-distribution.

Table S10 Solicited Local AE by Maximum severity [after any vaccination] (Safety Set)

	GBP510 (N=3029)				ChAdOx1-S (N=996)			
	Grade 1 (Mild)	Grade 2 (Moderate)	Grade 3 (Severe)	Grade 4 (Potentially Life Threatening)	Grade 1 (Mild)	Grade 2 (Moderate)	Grade 3 (Severe)	Grade 4 (Potentially Life Threatening)
Adverse Events after any vaccination, n(%)								
Injection Site Pain	1348(44.50)	293(9.67)	46(1.52)	0	414(41.57)	66(6.63)	6(0.60)	0
Injection Site Redness	101(3.33)	49(1.62)	9(0.30)	0	20(2.01)	0	0	0
Injection Site Swelling	123(4.06)	42(1.39)	3(0.10)	0	11(1.10)	1(0.10)	0	0

Note: Denominator of percentage is the number of participants in each group.

Adverse events are displayed as 'number of participants(percentage of participants)'.

If one subject experienced the same adverse event more than once, the adverse event is counted only once with the most severe category.

Table S11 Solicited Systemic AEs by Maximum Severity [after any vaccination] (Safety Set)

	GBP510 (N=3029)				ChAdOx1-S (N=996)			
	Grade 1 (Mild)	Grade 2 (Moderate)	Grade 3 (Severe)	Grade 4 (Potentially Life Threatening)	Grade 1 (Mild)	Grade 2 (Moderate)	Grade 3 (Severe)	Grade 4 (Potentially Life Threatening)
Adverse Events after any vaccination, n(%)								
Fever	260(8.58)	159(5.25)	55(1.82)	0	88(8.84)	45(4.52)	28(2.81)	1(0.10)
Nausea/Vomiting	178(5.88)	25(0.83)	0	0	63(6.33)	14(1.41)	1(0.10)	0
Diarrhea	136(4.49)	28(0.92)	3(0.10)	0	70(7.03)	10(1.00)	0	0
Headache	680(22.45)	200(6.60)	25(0.83)	0	258(25.90)	65(6.53)	8(0.80)	0
Fatigue	626(20.67)	253(8.35)	62(2.05)	0	205(20.58)	101(10.14)	21(2.11)	0
Myalgia	553(18.26)	306(10.10)	64(2.11)	0	198(19.88)	94(9.44)	15(1.51)	0
Arthralgia	295(9.74)	126(4.16)	26(0.86)	0	120(12.05)	48(4.82)	8(0.80)	0
Chills	456(15.05)	180(5.94)	49(1.62)	0	155(15.56)	70(7.03)	21(2.11)	0

Note: Denominator of percentage is the number of participants in each group.

Adverse events are displayed as 'number of participants(percentage of participants)'.
If one subject experienced the same adverse event more than once, the adverse event is counted only once with the most severe category.

Table S12 Unsolicited AE [after any vaccination] (Safety Set)

	GBP510 (N=3029)	ChAdOx1-S (N=996)	Total (N=4025)
Participants with Unsolicited AEs	402(13.27) [640]	145(14.56) [213]	547(13.59) [853]
Exact 95% Confidence Interval	[12.08, 14.53]	[12.43, 16.90]	[12.55, 14.69]
P-value [1]			0.3040 (c)
Severity			
Grade 0 (None)	58(9.06)	23(10.80)	81(9.50)
Grade 1 (Mild)	414(64.69)	121(56.81)	535(62.72)
Grade 2 (Moderate)	141(22.03)	51(23.94)	192(22.51)
Grade 3 (Severe)	26(4.06)	18(8.45)	44(5.16)
Grade 4 (Potentially Life Threatening)	1(0.16)	0	1(0.12)
Serious AE			
Yes	15(2.34)	9(4.23)	24(2.81)
No	625(97.66)	204(95.77)	829(97.19)
MAAE			
Hospitalization	14(8.64)	8(13.56)	22(9.95)
ER visit	10(6.17)	1(1.69)	11(4.98)
Other visit to a healthcare professional	138(85.19)	50(84.75)	188(85.07)
AESI			
Yes	2(0.31)	1(0.47)	3(0.35)
No	638(99.69)	212(99.53)	850(99.65)
Outcome			
Recovered/Resolved	568(88.75)	191(89.67)	759(88.98)
Recovering/Resolving	38(5.94)	11(5.16)	49(5.74)
Not recovered/Not Resolved	30(4.69)	7(3.29)	37(4.34)
Stabilized	27(4.22)	6(2.82)	33(3.87)
Not stabilized	3(0.47)	1(0.47)	4(0.47)
Recovered/Resolved with sequelae	0	0	0
Fatal	0	1(0.47)	1(0.12)
Unknown	4(0.63)	3(1.41)	7(0.82)
Causality			
Related	164(25.63)	59(27.70)	223(26.14)
Not-related	476(74.38)	154(72.30)	630(73.86)
Changes to IP vaccination			
Stop Vaccination (only if, prior to 2nd vaccination)	87(13.59)	23(10.80)	110(12.90)
Continue to Vaccination (only if, prior to 2nd vaccination)	268(41.88)	111(52.11)	379(44.43)
Unknown	0	0	0
Not Applicable (only if, after 2nd vaccination)	285(44.53)	79(37.09)	364(42.67)
Medication			
Yes	305(47.66)	108(50.70)	413(48.42)
No	335(52.34)	105(49.30)	440(51.58)
Participants with Unsolicited ADRs	106(3.50) [164]	41(4.12) [59]	147(3.65) [223]
Exact 95% Confidence Interval	[2.87, 4.22]	[2.97, 5.54]	[3.09, 4.28]
P-value [1]			0.3679 (c)
Severity			
Grade 0 (None)	0	0	0
Grade 1 (Mild)	120(73.17)	41(69.49)	161(72.20)
Grade 2 (Moderate)	40(24.39)	15(25.42)	55(24.66)
Grade 3 (Severe)	4(2.44)	3(5.08)	7(3.14)
Grade 4 (Potentially Life Threatening)	0	0	0

	GBP510 (N=3029)	ChAdOx1-S (N=996)	Total (N=4025)
Serious ADR			
Yes	1(0.61)	0	1(0.45)
No	163(99.39)	59(100.00)	222(99.55)
MAAE			
Hospitalization	1(6.67)	0	1(4.35)
ER visit	0	0	0
Other visit to a healthcare professional	14(93.33)	8(100.00)	22(95.65)
AESI			
Yes	1(0.61)	0	1(0.45)
No	163(99.39)	59(100.00)	222(99.55)
Outcome			
Recovered/Resolved	151(92.07)	55(93.22)	206(92.38)
Recovering/Resolving	9(5.49)	2(3.39)	11(4.93)
Not recovered/Not Resolved	4(2.44)	2(3.39)	6(2.69)
Stabilized	4(2.44)	2(3.39)	6(2.69)
Not stabilized	0	0	0
Recovered/Resolved with sequelae	0	0	0
Fatal	0	0	0
Unknown	0	0	0
Changes to IP vaccination			
Stop Vaccination (only if, prior to 2nd vaccination)	2(1.22)	0	2(0.90)
Continue to Vaccination (only if, prior to 2nd vaccination)	83(50.61)	45(76.27)	128(57.40)
Unknown	0	0	0
Not Applicable (only if, after 2nd vaccination)	79(48.17)	14(23.73)	93(41.70)
Medication			
Yes	43(26.22)	16(27.12)	59(26.46)
No	121(73.78)	43(72.88)	164(73.54)

AEs = adverse events, ADRs= adverse drug reactions, MAAEs = medically attended adverse events, AESIs = adverse events of special interest, IP = investigator product.

95% confidence interval was calculated by Clopper-Pearson Methods.

[1] Testing for between-treatment groups (chi-square test (c) or Fisher's exact test (f)).

Note: Denominator of percentage of participants is the number of participants in each group and denominator of percentage of events is the number of events in each group; Denominator of percentage of type of MAAEs is the number of events in each group with MAAEs.

Asymptomatic COVID-19 cases that symptom was 'No' in the [COVID-19 related Information] page of eCRF and symptom is not recorded on SAFETY DB were categorized as 'Grade 0 (None)'.
.

Table S13 Virologically-confirmed COVID-19 Observed within a Median 2.5-Months of Follow-up after 2nd Vaccination (Safety Set)

	GBP510 (N=3029)	ChAdOx1-S (N=996)
After any vaccination	152(5.02)	77(7.73)
Exact 95% Confidence Interval	[4.27, 5.86]	[6.15, 9.57]
P-value [1]	0.0013 (c)	
Severity		
Asymptomatic	30(0.99)	19(1.91)
Non-severe	122(4.03)	58(5.82)
Severe	0	0
Critical	0	0
<14 days after 1st vaccination	9(0.30)	1(0.10)
Exact 95% Confidence Interval	[0.14, 0.56]	[0.00, 0.56]
P-value [1]	0.4674 (f)	
Severity		
Asymptomatic	3(0.10)	0
Non-severe	6(0.20)	1(0.10)
Severe	0	0
Critical	0	0
≥ 14 days after 1st vaccination and before 2nd vaccination	32(1.06)	15(1.51)
Exact 95% Confidence Interval	[0.72, 1.49]	[0.85, 2.47]
P-value [1]	0.2519 (c)	
Severity		
Asymptomatic	10(0.33)	7(0.70)
Non-severe	22(0.73)	8(0.80)
Severe	0	0
Critical	0	0
After 2nd vaccination and <14 days after 2nd vaccination	6(0.20)	2(0.20)
Exact 95% Confidence Interval	[0.07, 0.43]	[0.02, 0.72]
P-value [1]	1.0000 (f)	
Severity		
Asymptomatic	3(0.10)	0
Non-severe	3(0.10)	2(0.20)
Severe	0	0
Critical	0	0
≥ 14 days after 2nd vaccination	105(3.47)	59(5.92)
Exact 95% Confidence Interval	[2.84, 4.18]	[4.54, 7.57]
P-value [1]	0.0007 (c)	
Severity		
Asymptomatic	14(0.46)	12(1.20)
Non-severe	91(3.00)	47(4.72)
Severe	0	0
Critical	0	0

[1] Testing for between-treatment groups (chi-square test (c) or Fisher's exact test (f)).

Note: Denominator of percentage is the number of participants in each group.

Table S14 Virologically-suspected COVID-19 Observed within a Median 2.5-Months of Follow-up after 2nd Vaccination (Safety set)

	GBP510 (N=3029)	ChAdOx1-S (N=996)
After any vaccination	86(2.84)	21(2.11)
Exact 95% Confidence Interval	[2.28, 3.49]	[1.31, 3.20]
P-value [1]	0.2136 (c)	
Severity		
Asymptomatic	39(1.29)	7(0.70)
Non-severe	47(1.55)	14(1.41)
Severe	0	0
Critical	0	0
<14 days after 1st vaccination	0	0
Exact 95% Confidence Interval	[0.00, 0.12]	[0.00, 0.37]
P-value [1]	NC	
≥ 14 days after 1st vaccination and before 2nd vaccination	36(1.19)	5(0.50)
Exact 95% Confidence Interval	[0.83, 1.64]	[0.16, 1.17]
P-value [1]	0.0612 (c)	
Severity		
Asymptomatic	33(1.09)	5(0.50)
Non-severe	3(0.10)	0
Severe	0	0
Critical	0	0
After 2nd vaccination and <14 days after 2nd vaccination	0	0
Exact 95% Confidence Interval	[0.00, 0.12]	[0.00, 0.37]
P-value [1]	NC	
≥ 14 days after 2nd vaccination	50(1.65)	16(1.61)
Exact 95% Confidence Interval	[1.23, 2.17]	[0.92, 2.60]
P-value [1]	0.9239 (c)	
Severity		
Asymptomatic	6(0.20)	2(0.20)
Non-severe	44(1.45)	14(1.41)
Severe	0	0
Critical	0	0


NC = not calculated.

[1] Testing for between-treatment groups (chi-square test (c) or Fisher's exact test (f)).

Note: Denominator of percentage is the number of participants in each group.

II. Supplementary Figures

Figure S1. Schema of Study Enrolment



* Approximately 20% of the participants in each treatment group was planned to be elderly population aged 65 years or older

Figure S2. Analysis Sets




Figure S3. Boxplot for the Natural Logarithmic of Titre by ELISA at Visit 2, 4, and 6 (Per-Protocol Set 1)




Figure S4. Cell-mediated Response FluoroSpot Assay Per-Protocol Set 1 [T cell: IFN γ]




Figure S5. Cell-mediated Response FluoroSpot Assay Per-Protocol Set 1 [T cell: IL-2]




Figure S6. Cell-mediated Response FluoroSpot Assay Per-Protocol Set 1 [T cell: TNF α]




Figure S7. Cell-mediated Response FluoroSpot Assay Per-Protocol Set 1 [T cell: IL-4]




Figure S8. Cell-mediated Response FACS Per-Protocol Set 1 [CD4+ T cell: IFN γ]




Figure S9. Cell-mediated Response FACS Per-Protocol Set 1 [CD4+ T cell: IL-2]




Figure S10. Cell-mediated Response FACS Per-Protocol Set 1 [CD4+ T cell: TNF α]





Figure S11. Cell-mediated Response FACS Per-Protocol Set 1 [CD4+ T cell: IL-4]



III supplementary Authors List

Name	Affiliation
Agathe Philippot, PharmD	GlaxoSmithKline Vaccines, Wavre, Belgium
Francesca Solmi, PhD	GlaxoSmithKline Vaccines, Wavre, Belgium
Maria Angeles Ceregado, PhD	GlaxoSmithKline Vaccines, Wavre, Belgium
Byoung-Shik Shim, PhD	International Vaccine Institute, Seoul, Republic of Korea
Sang Hwan Seo, PhD	International Vaccine Institute, Seoul, Republic of Korea
Simone D'Souza, Bcs.(Hons)	International Vaccine Institute, Seoul, Republic of Korea
Patchara Thaisrivichai, MSc	International Vaccine Institute, Seoul, Republic of Korea
Dr. Josefina Carlos, MD	University of The East-Ramon Magsaysay Memorial Medical Center Inc., Laguna 4030, Philippines
Dr. Edison Alberto, MD	Health Index Multispeciality Primary Health Care Clinic, Cavite, Philippines
Dr. Sorachai Nitayaphan MD, PhD	Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand
Dr. Winai Ratanasuwan, MD	Faculty of Medicine Siriraj Hospital, Mahidol University: Siriraj Hospital, Bangkok, Thailand
Dr. Piroon Mootsikapun, MD	Faculty of Medicine, Khon Kaen University: Sriganarind Hospital, Khon Kaen, Thailand
Dr. Romanee Chaiwarith, MD	Faculty of Medicine, Chiang Mai University: Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
Dr. Luong Chan Quang, MD	Hồ Chí Minh City Pasteur Institute, Hồ Chí Minh, Vietnam
Dr. Olena Karpenko, MD	Medical Center "Ok Clinic" of the International Institute for Clinical Studies, LLC, outpatient department, Kyiv, Ukraine
Dr. Tatiana Yurkiv, MD	Private Enterprise Private Manufacturing Company "Acinus", Diagnostic and Treatment Center, Kropyvnytskyi, Ukraine
Dr. Vitalii Kutovyi, MD	Communal non-profit enterprise "Kyiv city Hospital №6" of Executive Body of the Kyiv City Administration (Kyiv City State Administration), Kyiv, Ukraine
Dr. Angela Bartko, MD	Municipal Nonprofit Enterprise "Khmelnysky Regional Hospital for War Veterans" of Khmelnytsky Regional Council, Khmelnytskyi, Ukraine
Dr. Olga Gyrina, MD	Treatment and Diagnostic Center "Adonis-plus" LLC, Kyiv, Ukraine
Dr. Olga Barna, MD	Medical Center of Preventclinic LLC, Kyiv, Ukraine
Dr. Mykhailo Pugach, MD	LLC MC Blagomed, Kyiv, Ukraine
Dr. Claire Thurlow, MD	Southern Clinical Trials Tasman, Nelson, New Zealand
Dr. Simon Carson, MD	Southern Clinical Trials Christchurch, Wellington, New Zealand
Dr. Susan Smith, MD	Southern Clinical Trials Waitemata, Auckland, New Zealand
Dr. Mike Williams, MD	Lakeland Clinical Trials ROTORUA, RotoRua, New Zealand
Dr. Tiwini Hemi Senior, MD	Lakeland Clinical Trials WAIKATO RotoRua, New Zealand
Dr. Tim Humphrey, MD	Lakeland Clinical Trials Wellington, Upper Hutt, New Zealand

Dr. Davitt Sheahan, MD	Lakeland Clinical Trials Culloden, Tauranga, New Zealand
Hokeun Park, BS	Department of R&D, Clinical Strategy team, SK Bioscience, Seongnam, Republic of Korea
Yoon Yeong Lee, MS	Department of R&D, Clinical Operation team, SK Bioscience, Seongnam, Republic of Korea
Seung Gu Kang, BS	Department of R&D, Clinical Strategy team, SK Bioscience, Seongnam, Republic of Korea